1
|
Jovalekic A, Roé-Vellvé N, Koglin N, Quintana ML, Nelson A, Diemling M, Lilja J, Gómez-González JP, Doré V, Bourgeat P, Whittington A, Gunn R, Stephens AW, Bullich S. Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods. Eur J Nucl Med Mol Imaging 2023; 50:3276-3289. [PMID: 37300571 PMCID: PMC10542295 DOI: 10.1007/s00259-023-06279-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 05/19/2023] [Indexed: 06/12/2023]
Abstract
PURPOSE Amyloid positron emission tomography (PET) with [18F]florbetaben (FBB) is an established tool for detecting Aβ deposition in the brain in vivo based on visual assessment of PET scans. Quantitative measures are commonly used in the research context and allow continuous measurement of amyloid burden. The aim of this study was to demonstrate the robustness of FBB PET quantification. METHODS This is a retrospective analysis of FBB PET images from 589 subjects. PET scans were quantified with 15 analytical methods using nine software packages (MIMneuro, Hermes BRASS, Neurocloud, Neurology Toolkit, statistical parametric mapping (SPM8), PMOD Neuro, CapAIBL, non-negative matrix factorization (NMF), AmyloidIQ) that used several metrics to estimate Aβ load (SUVR, centiloid, amyloid load, and amyloid index). Six analytical methods reported centiloid (MIMneuro, standard centiloid, Neurology Toolkit, SPM8 (PET only), CapAIBL, NMF). All results were quality controlled. RESULTS The mean sensitivity, specificity, and accuracy were 96.1 ± 1.6%, 96.9 ± 1.0%, and 96.4 ± 1.1%, respectively, for all quantitative methods tested when compared to histopathology, where available. The mean percentage of agreement between binary quantitative assessment across all 15 methods and visual majority assessment was 92.4 ± 1.5%. Assessments of reliability, correlation analyses, and comparisons across software packages showed excellent performance and consistent results between analytical methods. CONCLUSION This study demonstrated that quantitative methods using both CE marked software and other widely available processing tools provided comparable results to visual assessments of FBB PET scans. Software quantification methods, such as centiloid analysis, can complement visual assessment of FBB PET images and could be used in the future for identification of early amyloid deposition, monitoring disease progression and treatment effectiveness.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Vincent Doré
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia
| | | | | | | | | | | |
Collapse
|
2
|
Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, Bourgeat P, Lopresti B, Huang K, Krishnadas N, Fripp J, Takado Y, Gogola A, Minhas D, Weimer R, Higuchi M, Stephens A, Hansson O, Doré V. CenTauR: Toward a universal scale and masks for standardizing tau imaging studies. Alzheimers Dement (Amst) 2023; 15:e12454. [PMID: 37424964 PMCID: PMC10326476 DOI: 10.1002/dad2.12454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 05/26/2023] [Accepted: 05/26/2023] [Indexed: 07/11/2023]
Abstract
INTRODUCTION Recently, an increasing number of tau tracers have become available. There is a need to standardize quantitative tau measures across tracers, supporting a universal scale. We developed several cortical tau masks and applied them to generate a tau imaging universal scale. METHOD One thousand forty-five participants underwent tau scans with either 18F-flortaucipir, 18F-MK6240, 18F-PI2620, 18F-PM-PBB3, 18F-GTP1, or 18F-RO948. The universal mask was generated from cognitively unimpaired amyloid beta (Aβ)- subjects and Alzheimer's disease (AD) patients with Aβ+. Four additional regional cortical masks were defined within the constraints of the universal mask. A universal scale, the CenTauRz, was constructed. RESULTS None of the regions known to display off-target signal were included in the masks. The CenTauRz allows robust discrimination between low and high levels of tau deposits. DISCUSSION We constructed several tau-specific cortical masks for the AD continuum and a universal standard scale designed to capture the location and degree of abnormality that can be applied across tracers and across centers. The masks are freely available at https://www.gaain.org/centaur-project.
Collapse
Affiliation(s)
- Victor L. Villemagne
- Department of PsychiatryUniversity of PittsburghPittsburghPennsylvaniaUSA
- Department of Molecular Imaging & TherapyAustin HealthMelbourneVictoriaAustralia
| | - Antoine Leuzy
- Clinical Memory Research UnitDepartment of Clinical SciencesLund UniversityMalmöSweden
| | | | | | - Hitoshi Shimada
- Department of Functional Brain ImagingNational Institutes for Quantum and Radiological Science and TechnologyChibaJapan
- Brain Research InstituteNiigata UniversityNiigataJapan
| | - Christopher C. Rowe
- Department of Molecular Imaging & TherapyAustin HealthMelbourneVictoriaAustralia
- Florey Department of Neurosciences & Mental HealthThe University of MelbourneMelbourneParkvilleAustralia
- The Australian Dementia Network (ADNeT)MelbourneVictoriaAustralia
| | - Pierrick Bourgeat
- Health and Biosecurity FlagshipThe Australian eHealth Research CentreCSIROBrisbaneQueenslandAustralia
| | - Brian Lopresti
- Department of RadiologyUniversity of PittsburghPittsburghPennsylvaniaUSA
| | - Kun Huang
- Department of Molecular Imaging & TherapyAustin HealthMelbourneVictoriaAustralia
| | - Natasha Krishnadas
- Department of Molecular Imaging & TherapyAustin HealthMelbourneVictoriaAustralia
- Florey Institute of Neurosciences & Mental HealthParkvilleVictoriaAustralia
| | - Jurgen Fripp
- Health and Biosecurity FlagshipThe Australian eHealth Research CentreCSIROBrisbaneQueenslandAustralia
| | - Yuhei Takado
- Department of Functional Brain ImagingNational Institutes for Quantum and Radiological Science and TechnologyChibaJapan
| | - Alexandra Gogola
- Department of RadiologyUniversity of PittsburghPittsburghPennsylvaniaUSA
| | - Davneet Minhas
- Department of RadiologyUniversity of PittsburghPittsburghPennsylvaniaUSA
| | | | - Makoto Higuchi
- Department of Functional Brain ImagingNational Institutes for Quantum and Radiological Science and TechnologyChibaJapan
| | | | - Oskar Hansson
- Clinical Memory Research UnitDepartment of Clinical SciencesLund UniversityMalmöSweden
- Memory ClinicSkåne University HospitalMalmöSweden
| | - Vincent Doré
- Department of Molecular Imaging & TherapyAustin HealthMelbourneVictoriaAustralia
- Health and Biosecurity FlagshipThe Australian eHealth Research CentreCSIROHeidelbergVictoriaAustralia
| | | |
Collapse
|
3
|
Collij LE, Salvadó G, de Wilde A, Altomare D, Shekari M, Gispert JD, Bullich S, Stephens A, Barkhof F, Scheltens P, Bouwman F, van der Flier WM. Quantification of [
18
F]florbetaben amyloid‐PET imaging in a mixed memory clinic population: The ABIDE project. Alzheimers Dement 2022. [DOI: 10.1002/alz.12886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 10/25/2022] [Accepted: 10/27/2022] [Indexed: 12/12/2022]
Affiliation(s)
- Lyduine E. Collij
- Department of Radiology and Nuclear Medicine Amsterdam University Medical Center Amsterdam Neuroscience Amsterdam The Netherlands
| | - Gemma Salvadó
- Barcelonaβeta Brain Research Center (BBRC) Pasqual Maragall Foundation Barcelona Spain
- Clinical Memory Research Unit Department of Clinical Sciences Lund University Malmö Sweden
| | - Arno de Wilde
- Department of Neurology Alzheimer Center Amsterdam Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The Netherlands
| | - Daniele Altomare
- Laboratory of Neuroimaging of Aging (LANVIE) University of Geneva Geneva Switzerland
- Memory Center Geneva University Hospitals Geneva Switzerland
| | - Mahnaz Shekari
- Barcelonaβeta Brain Research Center (BBRC) Pasqual Maragall Foundation Barcelona Spain
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Pompeu Fabra University Barcelona Spain
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center (BBRC) Pasqual Maragall Foundation Barcelona Spain
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Centro de Investigación Biomédica en Red de Bioingeniería Biomateriales y Nanomedicina (CIBER‐BBN) Madrid Spain
| | | | | | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine Amsterdam University Medical Center Amsterdam Neuroscience Amsterdam The Netherlands
- Centre for Medical Image Computing and Queen Square Institute of Neurology UCL London UK
| | - Philip Scheltens
- Department of Neurology Alzheimer Center Amsterdam Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The Netherlands
| | - Femke Bouwman
- Department of Neurology Alzheimer Center Amsterdam Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The Netherlands
| | - Wiesje M. van der Flier
- Department of Neurology Alzheimer Center Amsterdam Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The Netherlands
- Department of Epidemiology & Data Science Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam The Netherlands
| |
Collapse
|
4
|
Shekari M, García DV, Collij LE, Heeman F, Roé‐Vellvé N, Bullich S, Buckley C, Barkhof F, Farrar G, Pemberton H, Gispert JD. Evaluating the sensitivity of Centiloid quantification to pipeline design and image resoloution. Alzheimers Dement 2022. [DOI: 10.1002/alz.062330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Mahnaz Shekari
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Universitat Pompeu Fabra Barcelona Spain
| | - David Vállez García
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
| | - Lyduine E. Collij
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
| | - Fiona Heeman
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
| | | | | | | | - Frederik Barkhof
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
- University College London London United Kingdom
| | - Gill Farrar
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | - Hugh Pemberton
- Institute of Neurology and Centre for Medical Image Computing, University College London London United Kingdom
- GE Healthcare Pharmaceutical Diagnostics Amersham United Kingdom
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER‐BBN) Madrid Spain
| | | |
Collapse
|
5
|
Shekari M, García DV, Collij LE, Heeman F, Roé‐Vellvé N, Bullich S, Buckley C, Barkhof F, Farrar G, Pemberton H, Gispert JD. Evaluating the sensitivity of Centiloid quantification to pipeline design and image resolution. Alzheimers Dement 2022. [DOI: 10.1002/alz.067896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Mahnaz Shekari
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Universitat Pompeu Fabra Barcelona Spain
| | - David Vállez García
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
| | - Lyduine E. Collij
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
| | - Fiona Heeman
- Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117 Amsterdam Netherlands
| | | | | | | | - Frederik Barkhof
- Institute of Neurology and Centre for Medical Image Computing, University College London London United Kingdom
- Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Gill Farrar
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | - Hugh Pemberton
- Institute of Neurology and Centre for Medical Image Computing, University College London London United Kingdom
- GE Healthcare Pharmaceutical Diagnostics Amersham United Kingdom
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER‐BBN) Madrid Spain
| | | |
Collapse
|
6
|
Bohorquez SS, Constantinescu C, Manser PT, Gunn RN, Russell DS, Tonietto M, Bullich S, Stephens AW, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [
18
F]GTP1 and [
18
F]PI2620 in Alzheimer’s Disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.063517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | | | | | - Matteo Tonietto
- Roche Pharma Research and Early Development, FHoffmann‐La RocheLtd Basel Switzerland
| | | | | | | | - Gregory Klein
- Pharma Research and Early Development, F. Hoffmann‐La Roche Ltd. Basel Switzerland
| | | | | |
Collapse
|
7
|
Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roé-Vellvé N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study. Alzheimers Res Ther 2022; 14:105. [PMID: 35897078 PMCID: PMC9327167 DOI: 10.1186/s13195-022-01048-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 07/11/2022] [Indexed: 11/10/2022]
Abstract
Background The ability of 18F-PI-2620 PET to measure the spatial distribution of tau pathology in Alzheimer’s disease (AD) has been demonstrated in previous studies. The objective of this work was to evaluate tau deposition using 18F-PI-2620 PET in beta-amyloid positive subjects with a diagnosis of mild cognitive impairment (MCI) or mild AD dementia and characterize it with respect to amyloid deposition, cerebrospinal fluid (CSF) assessment, hippocampal volume, and cognition. Methods Subjects with a diagnosis of MCI due to AD or mild AD dementia and a visually amyloid-positive 18F-florbetaben PET scan (n=74, 76 ± 7 years, 38 females) underwent a baseline 18F-PI-2620 PET, T1-weighted magnetic resonance imaging (MRI), CSF assessment (Aβ42/Aβ40 ratio, p-tau, t-tau) (n=22) and several cognitive tests. A 1-year follow-up 18F-PI-2620 PET scans and cognitive assessments were done in 15 subjects. Results Percentage of visually tau-positive scans increased with amyloid-beta deposition measured in 18F-florbetaben Centiloids (CL) (7.7% (<36 CL), 80% (>83 CL)). 18F-PI-2620 standardized uptake value ratio (SUVR) was correlated with increased 18F-florbetaben CL in several regions of interest. Elevated 18F-PI-2620 SUVR (fusiform gyrus) was associated to high CSF p-tau and t-tau (p=0.0006 and p=0.01, respectively). Low hippocampal volume was associated with increased tau load at baseline (p=0.006 (mesial temporal); p=0.01 (fusiform gyrus)). Significant increases in tau SUVR were observed after 12 months, particularly in the mesial temporal cortex, fusiform gyrus, and inferior temporal cortex (p=0.04, p=0.047, p=0.02, respectively). However, no statistically significant increase in amyloid-beta load was measured over the observation time. The MMSE (Recall score), ADAS-Cog14 (Word recognition score), and CBB (One-card learning score) showed the strongest association with tau deposition at baseline. Conclusions The findings support the hypothesis that 18F-PI-2620 PET imaging of neuropathologic tau deposits may reflect underlying neurodegeneration in AD with significant correlations with hippocampal volume, CSF biomarkers, and amyloid-beta load. Furthermore, quantifiable increases in 18F-PI-2620 SUVR over a 12-month period in regions with early tau deposition are consistent with the hypothesis that cortical tau is associated with cognitive impairment. This study supports the utility of 18F-PI-2620 PET to assess tau deposits in an early AD population. Quantifiable tau load and its corresponding increase in early AD cases could be a relevant target engagement marker in clinical trials of anti-amyloid and anti-tau agents. Trial registration Data used in this manuscript belong to a tau PET imaging sub-study of the elenbecestat MissionAD Phase 3 program registered in ClinicalTrials.gov (NCT02956486; NCT03036280). Supplementary Information The online version contains supplementary material available at 10.1186/s13195-022-01048-x.
Collapse
|
8
|
Bohorquez SS, Constantinescu C, Manser PT, Gunn RN, Russell DS, Tonietto M, Bullich S, Stephens AW, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [
18
F]GTP1 and [
18
F]PI2620 in Alzheimer’s Disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.063513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | | | | | - Matteo Tonietto
- Roche Pharma Research and Early Development, FHoffmann‐La RocheLtd Basel Switzerland
| | | | | | | | - Gregory Klein
- Pharma Research and Early Development, F. Hoffmann‐La Roche Ltd. Basel Switzerland
| | | | | |
Collapse
|
9
|
Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, Alves IL, Garcia DV, Battle M, Buckley C, Stephens AW, Bullich S, Garibotto V, Barkhof F, Gispert JD, Farrar G. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nucl Med Mol Imaging 2022; 49:3508-3528. [PMID: 35389071 PMCID: PMC9308604 DOI: 10.1007/s00259-022-05784-y] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 03/25/2022] [Indexed: 12/15/2022]
Abstract
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo using positron emission tomography (PET), for which three fluorine-18 labelled radiotracers have been approved for clinical use. In clinical practice, trained readers will categorise scans as either Aβ positive or negative, based on visual inspection. Diagnostic decisions are often based on these reads and patient selection for clinical trials is increasingly guided by amyloid status. However, tracer deposition in the grey matter as a function of amyloid load is an inherently continuous process, which is not sufficiently appreciated through binary cut-offs alone. State-of-the-art methods for amyloid PET quantification can generate tracer-independent measures of Aβ burden. Recent research has shown the ability of these quantitative measures to highlight pathological changes at the earliest stages of the AD continuum and generate more sensitive thresholds, as well as improving diagnostic confidence around established binary cut-offs. With the recent FDA approval of aducanumab and more candidate drugs on the horizon, early identification of amyloid burden using quantitative measures is critical for enrolling appropriate subjects to help establish the optimal window for therapeutic intervention and secondary prevention. In addition, quantitative amyloid measurements are used for treatment response monitoring in clinical trials. In clinical settings, large multi-centre studies have shown that amyloid PET results change both diagnosis and patient management and that quantification can accurately predict rates of cognitive decline. Whether these changes in management reflect an improvement in clinical outcomes is yet to be determined and further validation work is required to establish the utility of quantification for supporting treatment endpoint decisions. In this state-of-the-art review, several tools and measures available for amyloid PET quantification are summarised and discussed. Use of these methods is growing both clinically and in the research domain. Concurrently, there is a duty of care to the wider dementia community to increase visibility and understanding of these methods.
Collapse
Affiliation(s)
- Hugh G Pemberton
- GE Healthcare, Amersham, UK.
- Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK.
- UCL Queen Square Institute of Neurology, University College London, London, UK.
| | - Lyduine E Collij
- Department of Radiology and Nuclear Medicine, Amsterdam Neurocience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Fiona Heeman
- Department of Radiology and Nuclear Medicine, Amsterdam Neurocience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Ariane Bollack
- Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK
| | - Mahnaz Shekari
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Gemma Salvadó
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | - Isadora Lopes Alves
- Department of Radiology and Nuclear Medicine, Amsterdam Neurocience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Brain Research Center, Amsterdam, The Netherlands
| | - David Vallez Garcia
- Department of Radiology and Nuclear Medicine, Amsterdam Neurocience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Mark Battle
- GE Healthcare, Amersham, UK
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden
| | | | | | | | - Valentina Garibotto
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Geneva, Geneva, Switzerland
- NIMTLab, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Frederik Barkhof
- Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK
- UCL Queen Square Institute of Neurology, University College London, London, UK
- Department of Radiology and Nuclear Medicine, Amsterdam Neurocience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain
| | | |
Collapse
|
10
|
Bullich S, de Souto Barreto P, Dortignac A, He L, Dray C, Valet P, Guiard BP. Apelin controls emotional behavior in age- and metabolic state-dependent manner. Psychoneuroendocrinology 2022; 140:105711. [PMID: 35305406 DOI: 10.1016/j.psyneuen.2022.105711] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 03/02/2022] [Accepted: 03/02/2022] [Indexed: 12/27/2022]
Abstract
Apelin is a small peptide secreted by the adipose tissue notably in conditions of obesity-induced hyper-insulinemia. Apelin exerts a range of physiological functions at the periphery including the improvement of insulin sensitivity and the increase of muscle strength or cardiac contractibility. Interestingly, the brain is endowed with a high density of APJ, the single target of apelin, and growing evidence suggests various central actions of this adipokine. Recent studies reported that the intracerebroventricular infusion of apelin modulates emotional states in middle age stressed animals. However, results are so far been mixed and have not allowed for definitive conclusions about the impact of apelin on anxio-depressive-like phenotype. This study aims 1) to evaluate whether serum apelin levels are associated with mood in older adults and 2) to determine the impact of the genetic apelin inactivation in 12-month old mice fed a standard diet (STD) or in 6-month old mice fed a high fat diet (HFD). A higher plasma apelin level was associated with higher depressive symptoms in older adults. In line with these clinical findings, 12-month old apelin knock-out (Ap-/-) mice displayed a spontaneous antidepressant-like phenotype. In a marked contrast, 6-month old Ap-/- mice harbored a higher degree of peripheral insulin resistance than wild-types in response to HFD and were more prone to develop anxiety while the depressive-like state was not modified. We also provided evidence that such anxious behavior was associated with an impairment of central serotonergic and dopaminergic neuronal activities. Finally, although the insulin sensitizing drug metformin failed to reverse HFD-induced insulin resistance in 6-month old Ap-/- mice, it reversed their anxious phenotype. These results emphasize a complex contribution of apelin in the regulation of emotional state that might depend on the age and the metabolic status of the animals. Further investigations are warranted to highlight the therapeutic potential of manipulating the apelinergic system in mood-related disorders.
Collapse
Affiliation(s)
- S Bullich
- Centre de Recherches sur la Cognition Animale (CRCA), Centre de Biologie Intégrative (CBI), CNRS UMR5169, Toulouse, France; Université de Toulouse III Université Paul Sabatier, Toulouse, France
| | - P de Souto Barreto
- Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 37 allées Jules Guesdes, 31000 Toulouse, France; CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, Toulouse, France
| | - A Dortignac
- Université de Toulouse III Université Paul Sabatier, Toulouse, France; Restore, a geroscience and rejuvenation research center, UMR 1301-Inserm, 5070-CNRS EFS, France
| | - L He
- Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 37 allées Jules Guesdes, 31000 Toulouse, France; CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, Toulouse, France
| | - C Dray
- Université de Toulouse III Université Paul Sabatier, Toulouse, France; Restore, a geroscience and rejuvenation research center, UMR 1301-Inserm, 5070-CNRS EFS, France
| | - P Valet
- Université de Toulouse III Université Paul Sabatier, Toulouse, France; Restore, a geroscience and rejuvenation research center, UMR 1301-Inserm, 5070-CNRS EFS, France
| | - B P Guiard
- Centre de Recherches sur la Cognition Animale (CRCA), Centre de Biologie Intégrative (CBI), CNRS UMR5169, Toulouse, France; Université de Toulouse III Université Paul Sabatier, Toulouse, France.
| |
Collapse
|
11
|
Wardak M, Sonni I, Fan AP, Minamimoto R, Jamali M, Hatami N, Zaharchuk G, Fischbein N, Nagpal S, Li G, Koglin N, Berndt M, Bullich S, Stephens AW, Dinkelborg LM, Abel T, Manning HC, Rosenberg J, Chin FT, Sam Gambhir S, Mittra ES. 18F-FSPG PET/CT Imaging of System x C- Transporter Activity in Patients with Primary and Metastatic Brain Tumors. Radiology 2022; 303:620-631. [PMID: 35191738 DOI: 10.1148/radiol.203296] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Background The PET tracer (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) targets the system xC- cotransporter, which is overexpressed in various tumors. Purpose To assess the role of 18F-FSPG PET/CT in intracranial malignancies. Materials and Methods Twenty-six patients (mean age, 54 years ± 12; 17 men; 48 total lesions) with primary brain tumors (n = 17) or brain metastases (n = 9) were enrolled in this prospective, single-center study (ClinicalTrials.gov identifier: NCT02370563) between November 2014 and March 2016. A 30-minute dynamic brain 18F-FSPG PET/CT scan and a static whole-body (WB) 18F-FSPG PET/CT scan at 60-75 minutes were acquired. Moreover, all participants underwent MRI, and four participants underwent fluorine 18 (18F) fluorodeoxyglucose (FDG) PET imaging. PET parameters and their relative changes were obtained for all lesions. Kinetic modeling was used to estimate the 18F-FSPG tumor rate constants using the dynamic and dynamic plus WB PET data. Imaging parameters were correlated to lesion outcomes, as determined with follow-up MRI and/or pathologic examination. The Mann-Whitney U test or Student t test was used for group mean comparisons. Receiver operating characteristic curve analysis was used for performance comparison of different decision measures. Results 18F-FSPG PET/CT helped identify all 48 brain lesions. The mean tumor-to-background ratio (TBR) on the whole-brain PET images at the WB time point was 26.6 ± 24.9 (range: 2.6-150.3). When 18F-FDG PET was performed, 18F-FSPG permitted visualization of non-18F-FDG-avid lesions or allowed better lesion differentiation from surrounding tissues. In participants with primary brain tumors, the predictive accuracy of the relative changes in influx rate constant Ki and maximum standardized uptake value to discriminate between poor and good lesion outcomes were 89% and 81%, respectively. There were significant differences in the 18F-FSPG uptake curves of lesions with good versus poor outcomes in the primary brain tumor group (P < .05) but not in the brain metastases group. Conclusion PET/CT imaging with (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) helped detect primary brain tumors and brain metastases with a high tumor-to-background ratio. Relative changes in 18F-FSPG uptake with multi-time-point PET appear to be helpful in predicting lesion outcomes. Clinical trial registration no. NCT02370563 © RSNA, 2022 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Mirwais Wardak
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Ida Sonni
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Audrey P Fan
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Ryogo Minamimoto
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Mehran Jamali
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Negin Hatami
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Greg Zaharchuk
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Nancy Fischbein
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Seema Nagpal
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Gordon Li
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Norman Koglin
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Mathias Berndt
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Santiago Bullich
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Andrew W Stephens
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Ludger M Dinkelborg
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Ty Abel
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - H Charles Manning
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Jarrett Rosenberg
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Frederick T Chin
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Sanjiv Sam Gambhir
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| | - Erik S Mittra
- From the Department of Radiology, Molecular Imaging Program at Stanford (MIPS) (M.W., I.S., A.P.F., R.M., M.J., N.H., G.Z., N.F., J.R., F.T.C., S.S.G., E.S.M.), Department of Neurosurgery (N.F., S.N., G.L.), and Department of Neurology and Neurological Sciences (N.F., S.N., G.L.), Stanford University School of Medicine, Stanford, Calif; Department of Molecular and Medical Pharmacology, UCLA Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, Calif (I.S.); Department of Biomedical Engineering, Department of Neurology, University of California, Davis, Davis, Calif (A.P.F.); Stanford Bio-X (M.W., G.Z., G.L., F.T.C., S.S.G.) and Departments of Bioengineering (S.S.G.) and Materials Science & Engineering (S.S.G.), Stanford University, Stanford, Calif; Life Molecular Imaging GmbH, Berlin, Germany (N.K., M.B., S.B., A.W.S., L.M.D.); Department of Pathology, Microbiology and Immunology (T.A.) and Department of Radiology and Radiological Sciences, Institute of Imaging Science, Center for Molecular Probes (H.C.M.), Vanderbilt University Medical Center, Nashville, Tenn; and Department of Cancer Systems Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex (H.C.M.)
| |
Collapse
|
12
|
Buckley C, Gispert JD, Altomare D, Moro C, Bullich S, Caprioglio C, Scheltens P, Van Berckel BN, Collij LE, Alves IL, Berkhof J, Garibotto V, Delrieu J, Molinuevo J, Drzezga A, Jessen F, Nordberg AK, Walker Z, Demonet J, Gismondi R, Battle MR, Farrar G, Stephens AW, Barkhof F, Frisoni G. Quantitative amyloid PET in the AMYPAD diagnostic and patient management study. Alzheimers Dement 2021. [DOI: 10.1002/alz.055940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Hospital del Mar Medical Research Institute (IMIM) Barcelona Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER‐BBN) Madrid Spain
- Pompeu Fabra University Barcelona Spain
| | | | | | | | | | | | - Bary N.M. Van Berckel
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Lyduine E. Collij
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Isadora Lopes Alves
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | | | | | | | - Jose Molinuevo
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- H. Lundbeck A/S Copenhagen Denmark
| | - Alexander Drzezga
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine Cologne Germany
- Institute of Neuroscience and Medicine, Research Center Jülich Jülich Germany
- German Center for Neurodegenerative Diseases (DZNE) Bonn/Cologne Germany
| | - Frank Jessen
- German Center for Neurodegenerative Diseases (DZNE) Bonn/Cologne Germany
| | - Agneta K. Nordberg
- Center for Alzheimer Research Karolinska Institutet, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Huddinge Sweden
- Karolinska University Hospital, Theme Aging Stockholm Sweden
| | - Zuzana Walker
- North Essex Partnership University NHS Foundation Trust Chelmsford United Kingdom
- Division of Psychiatry, University College London London United Kingdom
| | - Jean‐François Demonet
- Department of Clinical Neurosciences, Leenaards Memory Centre, Centre Hospitalier Universitaire Vaudois and University of Lausanne Lausanne Switzerland
| | | | - Mark R. Battle
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | - Gill Farrar
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | | | - Frederik Barkhof
- Institutes of Neurology and Healthcare Engineering, University College London London United Kingdom
- Amsterdam UMC, VU University Medical Center Amsterdam Netherlands
| | | | | |
Collapse
|
13
|
Shekari M, Salvadó G, Battle MR, Collij LE, Heeman F, Alves IL, Palombit A, Buckley CJ, Farrar G, Bullich S, Visser PJ, Scheltens P, Barkhof F, Gispert JD. Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. Alzheimers Dement 2021. [DOI: 10.1002/alz.055726] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Mahnaz Shekari
- Universitat Pompeu Fabra Barcelona Spain
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
| | - Gemma Salvadó
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
| | - Mark R Battle
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | - Lyduine E. Collij
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Fiona Heeman
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Isadora Lopes Alves
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | | | - Chris J Buckley
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | - Gill Farrar
- GE Healthcare, Pharmaceutical Diagnostics Amersham United Kingdom
| | | | - Pieter Jelle Visser
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center Amsterdam Netherlands
| | | | - Frederik Barkhof
- Centre for Medical Imaging Computing, Faculty of Engineering, University College London London United Kingdom
- Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC Amsterdam Netherlands
| | - Juan Domingo Gispert
- IMIM (Hospital del Mar Medical Research Institute) Barcelona Spain
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation Barcelona Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER‐BBN) Madrid Spain
| | | |
Collapse
|
14
|
Dore V, Bohorquez SS, Leuzy A, Shimada H, Bullich S, Bourgeat P, Burnham SC, Huang K, Krishnadas N, Fripp J, Takado Y, Stephens AW, Weimer R, Rowe CC, Higuchi M, Hansson O, Villemagne VL. Towards a universal cortical tau sampling mask. Alzheimers Dement 2021. [DOI: 10.1002/alz.055816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Vincent Dore
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
| | | | - Antoine Leuzy
- Clinical Memory Research Unit, Lund University Malmö Sweden
| | - Hitoshi Shimada
- National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba Japan
- Brain Research Institute, Niigata University Niigata Japan
| | | | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | | | - Kun Huang
- Austin Health Melbourne VIC Australia
| | - Natasha Krishnadas
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Yuhei Takado
- National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba Japan
| | | | | | - Christopher C Rowe
- The University of Melbourne Melbourne VIC Australia
- Australian Dementia Network (ADNeT) Melbourne Australia
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Makoto Higuchi
- National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba Japan
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund University Lund Sweden
- Memory Clinic, Skåne University Hospital Malmö Sweden
| | - Victor L Villemagne
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health Melbourne VIC Australia
- The University of Pittsburgh Pittsburgh PA USA
| |
Collapse
|
15
|
Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, Bullich S, DeSanti S, Jagust WJ, Landau SM. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther 2021; 13:99. [PMID: 33971965 PMCID: PMC8111744 DOI: 10.1186/s13195-021-00836-1] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Accepted: 04/26/2021] [Indexed: 11/16/2022]
Abstract
Background Inconsistent positivity thresholds, image analysis pipelines, and quantitative outcomes are key challenges of multisite studies using more than one β-amyloid (Aβ) radiotracer in positron emission tomography (PET). Variability related to these factors contributes to disagreement and lack of replicability in research and clinical trials. To address these problems and promote Aβ PET harmonization, we used [18F]florbetaben (FBB) and [18F]florbetapir (FBP) data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to derive (1) standardized Centiloid (CL) transformations and (2) internally consistent positivity thresholds based on separate young control samples. Methods We analyzed Aβ PET data using a native-space, automated image processing pipeline that is used for PET quantification in many large, multisite AD studies and trials and made available to the research community. With this pipeline, we derived SUVR-to-CL transformations using the Global Alzheimer’s Association Interactive Network data; we used reference regions for cross-sectional (whole cerebellum) and longitudinal (subcortical white matter, brain stem, whole cerebellum) analyses. Finally, we developed a FBB positivity threshold using an independent young control sample (N=62) with methods parallel to our existing FBP positivity threshold and validated the FBB threshold using a data-driven approach in ADNI participants (N=295). Results The FBB threshold based on the young sample (1.08; 18 CL) was consistent with that of the data-driven approach (1.10; 21 CL), and the existing FBP threshold converted to CL with the derived transformation (1.11; 20 CL). The following equations can be used to convert whole cerebellum- (cross-sectional) and composite- (longitudinal) normalized FBB and FBP data quantified with the native-space pipeline to CL units: [18F]FBB: CLwhole cerebellum = 157.15 × SUVRFBB − 151.87; threshold=1.08, 18 CL [18F]FBP: CLwhole cerebellum = 188.22 × SUVRFBP − 189.16; threshold=1.11, 20 CL [18F]FBB: CLcomposite = 244.20 × SUVRFBB − 170.80 [18F]FBP: CLcomposite = 300.66 × SUVRFBP − 208.84 Conclusions FBB and FBP positivity thresholds derived from independent young control samples and quantified using an automated, native-space approach result in similar CL values. These findings are applicable to thousands of available and anticipated outcomes analyzed using this pipeline and shared with the scientific community. This work demonstrates the feasibility of harmonized PET acquisition and analysis in multisite PET studies and internal consistency of positivity thresholds in standardized units. Supplementary Information The online version contains supplementary material available at 10.1186/s13195-021-00836-1.
Collapse
Affiliation(s)
- Sarah K Royse
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
| | - Davneet S Minhas
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Brian J Lopresti
- Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Alice Murphy
- Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
| | - Tyler Ward
- Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
| | - Robert A Koeppe
- Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, USA
| | | | | | - William J Jagust
- Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
| | - Susan M Landau
- Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
| | | |
Collapse
|
16
|
Bullich S, Roé-Vellvé N, Marquié M, Landau SM, Barthel H, Villemagne VL, Sanabria Á, Tartari JP, Sotolongo-Grau O, Doré V, Koglin N, Müller A, Perrotin A, Jovalekic A, De Santi S, Tárraga L, Stephens AW, Rowe CC, Sabri O, Seibyl JP, Boada M. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther 2021; 13:67. [PMID: 33773598 PMCID: PMC8005243 DOI: 10.1186/s13195-021-00807-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 03/10/2021] [Indexed: 03/26/2023]
Abstract
BACKGROUND A low amount and extent of Aβ deposition at early stages of Alzheimer's disease (AD) may limit the use of previously developed pathology-proven composite SUVR cutoffs. This study aims to characterize the population with earliest abnormal Aβ accumulation using 18F-florbetaben PET. Quantitative thresholds for the early (SUVRearly) and established (SUVRestab) Aβ deposition were developed, and the topography of early Aβ deposition was assessed. Subsequently, Aβ accumulation over time, progression from mild cognitive impairment (MCI) to AD dementia, and tau deposition were assessed in subjects with early and established Aβ deposition. METHODS The study population consisted of 686 subjects (n = 287 (cognitively normal healthy controls), n = 166 (subjects with subjective cognitive decline (SCD)), n = 129 (subjects with MCI), and n = 101 (subjects with AD dementia)). Three categories in the Aβ-deposition continuum were defined based on the developed SUVR cutoffs: Aβ-negative subjects, subjects with early Aβ deposition ("gray zone"), and subjects with established Aβ pathology. RESULTS SUVR using the whole cerebellum as the reference region and centiloid (CL) cutoffs for early and established amyloid pathology were 1.10 (13.5 CL) and 1.24 (35.7 CL), respectively. Cingulate cortices and precuneus, frontal, and inferior lateral temporal cortices were the regions showing the initial pathological tracer retention. Subjects in the "gray zone" or with established Aβ pathology accumulated more amyloid over time than Aβ-negative subjects. After a 4-year clinical follow-up, none of the Aβ-negative or the gray zone subjects progressed to AD dementia while 91% of the MCI subjects with established Aβ pathology progressed. Tau deposition was infrequent in those subjects without established Aβ pathology. CONCLUSIONS This study supports the utility of using two cutoffs for amyloid PET abnormality defining a "gray zone": a lower cutoff of 13.5 CL indicating emerging Aβ pathology and a higher cutoff of 35.7 CL where amyloid burden levels correspond to established neuropathology findings. These cutoffs define a subset of subjects characterized by pre-AD dementia levels of amyloid burden that precede other biomarkers such as tau deposition or clinical symptoms and accelerated amyloid accumulation. The determination of different amyloid loads, particularly low amyloid levels, is useful in determining who will eventually progress to dementia. Quantitation of amyloid provides a sensitive measure in these low-load cases and may help to identify a group of subjects most likely to benefit from intervention. TRIAL REGISTRATION Data used in this manuscript belong to clinical trials registered in ClinicalTrials.gov ( NCT00928304 , NCT00750282 , NCT01138111 , NCT02854033 ) and EudraCT (2014-000798-38).
Collapse
Affiliation(s)
- Santiago Bullich
- Life Molecular Imaging GmbH, Tegeler Str. 6-7, 13353, Berlin, Germany.
| | - Núria Roé-Vellvé
- Life Molecular Imaging GmbH, Tegeler Str. 6-7, 13353, Berlin, Germany
| | - Marta Marquié
- Fundació ACE Institut Català de Neurociències Aplicades, Research Center and Memory Unit - Universitat Internacional de Catalunya (UIC), Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Susan M Landau
- Helen Wills Neuroscience Institute, University of California, Berkeley and Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - Henryk Barthel
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - Victor L Villemagne
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.,Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health, Melbourne, Victoria, Australia
| | - Ángela Sanabria
- Fundació ACE Institut Català de Neurociències Aplicades, Research Center and Memory Unit - Universitat Internacional de Catalunya (UIC), Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Juan Pablo Tartari
- Fundació ACE Institut Català de Neurociències Aplicades, Research Center and Memory Unit - Universitat Internacional de Catalunya (UIC), Barcelona, Spain
| | - Oscar Sotolongo-Grau
- Fundació ACE Institut Català de Neurociències Aplicades, Research Center and Memory Unit - Universitat Internacional de Catalunya (UIC), Barcelona, Spain
| | - Vincent Doré
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.,The Australian e-Health Research Centre, Health and Biosecurity, CSIRO, Melbourne, Victoria, Australia
| | - Norman Koglin
- Life Molecular Imaging GmbH, Tegeler Str. 6-7, 13353, Berlin, Germany
| | - Andre Müller
- Life Molecular Imaging GmbH, Tegeler Str. 6-7, 13353, Berlin, Germany
| | - Audrey Perrotin
- Life Molecular Imaging GmbH, Tegeler Str. 6-7, 13353, Berlin, Germany
| | | | | | - Lluís Tárraga
- Fundació ACE Institut Català de Neurociències Aplicades, Research Center and Memory Unit - Universitat Internacional de Catalunya (UIC), Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| | - Andrew W Stephens
- Life Molecular Imaging GmbH, Tegeler Str. 6-7, 13353, Berlin, Germany
| | - Christopher C Rowe
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health, Melbourne, Victoria, Australia
| | - Osama Sabri
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | | | - Mercè Boada
- Fundació ACE Institut Català de Neurociències Aplicades, Research Center and Memory Unit - Universitat Internacional de Catalunya (UIC), Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
17
|
Heeman F, Yaqub M, Lopes Alves I, Heurling K, Bullich S, Gispert JD, Boellaard R, Lammertsma AA. Simulating the effect of cerebral blood flow changes on regional quantification of [ 18F]flutemetamol and [ 18F]florbetaben studies. J Cereb Blood Flow Metab 2021; 41:579-589. [PMID: 32281514 PMCID: PMC7907983 DOI: 10.1177/0271678x20918029] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Global and regional changes in cerebral blood flow (CBF) can result in biased quantitative estimates of amyloid load by PET imaging. Therefore, the current simulation study assessed effects of these changes on amyloid quantification using a reference tissue approach for [18F]flutemetamol and [18F]florbetaben. Previously validated pharmacokinetic rate constants were used to simulate time-activity curves (TACs) corresponding to full dynamic and dual-time-window acquisition protocols. CBF changes were simulated by varying the tracer delivery (K1) from +25 to -25%. The standardized uptake value ratio (SUVr) was computed and TACs were fitted using reference Logan (RLogan) and the simplified reference tissue model (SRTM) to obtain the relative delivery rate (R1) and volume of distribution ratio (DVR). RLogan was least affected by CBF changes (χ2 = 583 p < 0.001, χ2 = 81 p < 0.001, for [18F]flutemetamol and [18F]florbetaben, respectively) and the extent of CBF sensitivity generally increased for higher levels of amyloid. Further, SRTM-derived R1 changes correlated well with simulated CBF changes (R2 > 0.95) and SUVr's sensitivity to CBF changes improved for later uptake-times, with the exception of [18F]flutemetamol cortical changes. In conclusion, RLogan is the preferred method for amyloid quantification of [18F]flutemetamol and [18F]florbetaben studies and SRTM could be additionally used for obtaining a CBF proxy.
Collapse
Affiliation(s)
- Fiona Heeman
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Maqsood Yaqub
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Isadora Lopes Alves
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam, Netherlands
| | | | | | - Juan D Gispert
- Barcelonaβeta Brain Research Centre, Pasqual Maragall Foundation, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.,Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Ronald Boellaard
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam, Netherlands
| | - Adriaan A Lammertsma
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Amsterdam, Netherlands
| | | |
Collapse
|
18
|
Roé‐Vellvé N, Bullich S, Marquie M, Barthel H, Villemagne VLL, Sanabria A, Tartari JP, Sotolongo‐Grau O, Dore V, Koglin N, Mueller A, Perrotin A, Jovalekic A, de Santi S, Tarraga L, Stephens AW, Rowe CC, Sabri O, Seibyl J, Boada M. Quantitative thresholds for
18
F‐florbetaben PET for the detection of low amyloid load. Alzheimers Dement 2020. [DOI: 10.1002/alz.042933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Núria Roé‐Vellvé
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | - Santiago Bullich
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | - Marta Marquie
- On behalf of the AMYPAD consortium Brussels Belgium
- Research Center and Memory Clinic, Fundació ACE Institut Català de Neurociències Aplicades Universitat Internacional de Catalunya (UIC) Barcelona Spain
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases National Institute of Health Carlos III Madrid Spain
- FACEHBI Study Group Barcelona Spain
| | - Henryk Barthel
- Department of Nuclear Medicine University of Leipzig Leipzig Germany
| | - Victor LL Villemagne
- Departments of Medicine and Molecular Imaging University of Melbourne, Austin Health Melbourne Australia
| | - Angela Sanabria
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases National Institute of Health Carlos III Madrid Spain
- FACEHBI Study Group Barcelona Spain
- Research Center and Memory Clinic Fundació ACE Institut Català de Neurociències Aplicades Universitat Internacional de Catalunya Barcelona Spain
| | - Juan Pablo Tartari
- FACEHBI Study Group Barcelona Spain
- Research Center and Memory Clinic Fundació ACE Institut Català de Neurociències Aplicades Universitat Internacional de Catalunya Barcelona Spain
| | - Oscar Sotolongo‐Grau
- FACEHBI Study Group Barcelona Spain
- Research Center and Memory Clinic Fundació ACE Institut Català de Neurociències Aplicades Universitat Internacional de Catalunya Barcelona Spain
| | - Vincent Dore
- Departments of Medicine and Molecular Imaging University of Melbourne, Austin Health Melbourne Australia
| | - Norman Koglin
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | - Andre Mueller
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | - Audrey Perrotin
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | - Aleksandar Jovalekic
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | | | - Lluis Tarraga
- On behalf of the AMYPAD consortium Brussels Belgium
- Research Center and Memory Clinic, Fundació ACE Institut Català de Neurociències Aplicades Universitat Internacional de Catalunya (UIC) Barcelona Spain
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases National Institute of Health Carlos III Madrid Spain
- FACEHBI Study Group Barcelona Spain
| | - Andrew W Stephens
- Life Molecular Imaging GmbH Berlin Germany
- On behalf of the AMYPAD consortium Brussels Belgium
| | - Christopher C Rowe
- Departments of Medicine and Molecular Imaging University of Melbourne, Austin Health Melbourne Australia
| | - Osama Sabri
- Department of Nuclear Medicine University of Leipzig Leipzig Germany
| | | | - Mercè Boada
- Research Center and Memory Clinic, Fundació ACE Institut Català de Neurociències Aplicades Universitat Internacional de Catalunya (UIC) Barcelona Spain
- CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases National Institute of Health Carlos III Madrid Spain
- FACEHBI Study Group Barcelona Spain
- ACE Foundation Barcelona Spain
| |
Collapse
|
19
|
Bullich S, Salvadó G, Alves IL, Marquié M, Stephens AW, Gispert JD, Molinuevo JL, Buckley C, Boada M, Barkhof F. Converging evidence for a “gray‐zone” of amyloid burden and its relevance. Alzheimers Dement 2020. [DOI: 10.1002/alz.044786] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Santiago Bullich
- AMYPAD Consortium Brussels Belgium
- Life Molecular Imaging GmbH Berlin Germany
| | - Gemma Salvadó
- AMYPAD Consortium Brussels Belgium
- Barcelonaβeta Brain Research Center (BBRC) Pasqual Maragall Foundation Barcelona Spain
- For the ALFA study Barcelona Spain
| | - Isadora Lopes Alves
- AMYPAD Consortium Brussels Belgium
- Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam Netherlands
| | - Marta Marquié
- AMYPAD Consortium Brussels Belgium
- Fundació ACE Barcelona Alzheimer Treatment & Research Center Barcelona Spain
- FACEHBI Study Group Barcelona Spain
| | - Andrew W Stephens
- AMYPAD Consortium Brussels Belgium
- Life Molecular Imaging GmbH Berlin Germany
| | - Juan Domingo Gispert
- AMYPAD Consortium Brussels Belgium
- Barcelonaβeta Brain Research Center (BBRC) Pasqual Maragall Foundation Barcelona Spain
- For the ALFA study Barcelona Spain
| | - Jose Luis Molinuevo
- AMYPAD Consortium Brussels Belgium
- Barcelonaβeta Brain Research Center (BBRC) Pasqual Maragall Foundation Barcelona Spain
- For the ALFA study Barcelona Spain
| | | | - Mercè Boada
- Fundació ACE Barcelona Alzheimer Treatment & Research Center Barcelona Spain
- FACEHBI Study Group Barcelona Spain
- Fundació ACE Barcelona Alzheimer Treatment and Research Center Barcelona Spain
| | - Frederik Barkhof
- AMYPAD Consortium Brussels Belgium
- Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam Netherlands
- UCL Institute of Neurology London United Kingdom
| |
Collapse
|
20
|
Park SY, Mosci C, Kumar M, Wardak M, Koglin N, Bullich S, Mueller A, Berndt M, Stephens AW, Chin FT, Gambhir SS, Mittra ES. Initial evaluation of (4S)-4-(3-[ 18F]fluoropropyl)-L-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma. EJNMMI Res 2020; 10:100. [PMID: 32857284 PMCID: PMC7455665 DOI: 10.1186/s13550-020-00678-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Accepted: 07/28/2020] [Indexed: 01/17/2023] Open
Abstract
Purpose (4S)-4-(3-[18F]Fluoropropyl)-l-glutamic acid ([18F]FSPG) measures system xC− transporter activity and shows promise for oncologic imaging. We present data on tumor uptake of this radiopharmaceutical in human subjects with head and neck cancer (HNC), colorectal cancer (CRC), and non-Hodgkin lymphoma (NHL). Methods A total of 15 subjects with HNC (n = 5), CRC (n = 5), or NHL (n = 5) were recruited (mean age 66.2 years, range 44–87 years). 301.4 ± 28.1 MBq (8.1 ± 0.8 mCi) of [18F]FSPG was given intravenously to each subject, and 3 PET/CT scans were obtained 0–2 h post-injection. All subjects also had a positive [18F]FDG PET/CT scan within 1 month prior to the [18F]FSPG PET scan. Semi-quantitative and visual comparisons of the [18F]FSPG and [18F]FDG scans were performed. Results [18F]FSPG showed strong uptake in all but one HNC subject. The lack of surrounding brain uptake facilitated tumor delineation in the HNC patients. [18F]FSPG also showed tumor uptake in all CRC subjects, but variable uptake in the NHL subjects. While the absolute [18F]FDG SUV values were comparable or higher than [18F]FSPG, the tumor-to-background SUV ratios were greater with [18F]FSPG than [18F]FDG. Conclusions [18F]FSPG PET/CT showed promising results across 15 subjects with 3 different cancer types. Concordant visualization was mostly observed between [18F]FSPG and [18F]FDG PET/CT images, with some inter- and intra-individual uptake variability potentially reflecting differences in tumor biology. The tumor-to-background ratios were greater with [18F]FSPG than [18F]FDG in the cancer types evaluated. Future studies based on larger numbers of subjects and those with a wider array of primary and recurrent or metastatic tumors are planned to further evaluate the utility of this novel tracer.
Collapse
Affiliation(s)
- Sonya Y Park
- Department of Radiology, Division of Nuclear Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.,Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
| | - Camila Mosci
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
| | - Meena Kumar
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
| | - Mirwais Wardak
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
| | - Norman Koglin
- Bayer Pharma AG, Berlin, Germany.,Life Molecular Imaging GmbH, Berlin, Germany
| | | | - Andre Mueller
- Bayer Pharma AG, Berlin, Germany.,Life Molecular Imaging GmbH, Berlin, Germany
| | - Mathias Berndt
- Bayer Pharma AG, Berlin, Germany.,Life Molecular Imaging GmbH, Berlin, Germany
| | - Andrew W Stephens
- Bayer Pharma AG, Berlin, Germany.,Life Molecular Imaging GmbH, Berlin, Germany
| | - Frederick T Chin
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
| | - Sanjiv S Gambhir
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.,Department of Bioengineering, Stanford University, Stanford, CA, USA.,Department of Materials Science & Engineering, Stanford University, Stanford, CA, USA.,Bio-X Program, Stanford University, Stanford, CA, USA
| | - Erik S Mittra
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA. .,Department of Diagnostic Radiology, Division of Nuclear Medicine & Molecular Imaging, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Mail Code L340, Portland, OR, 97239, USA.
| |
Collapse
|
21
|
Leuzy A, Heurling K, De Santi S, Bullich S, Hansson O, Lilja J. Validation of a spatial normalization method using a principal component derived adaptive template for [ 18F]florbetaben PET. Am J Nucl Med Mol Imaging 2020; 10:161-167. [PMID: 32929394 PMCID: PMC7486549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Accepted: 08/04/2020] [Indexed: 06/11/2023]
Abstract
Quantification may help in the context of amyloid-β positron emission tomography (PET). Quantification typically requires that PET images be spatially normalized, a process that can be subject to bias. We herein aimed to test whether a principal component approach (PCA) previously applied to [18F]flutemetamol PET extends to [18F]florbetaben. PCA was applied to [18F]florbetaben PET data for 132 subjects (70 Alzheimer dementia, 62 controls) and used to generate an adaptive synthetic template. Spatial normalization of [18F]florbetaben data using this approach was compared to that achieved using SPM12's magnetic resonance (MR) imaging driven algorithm. The two registration methods showed high agreement and minimal difference in standardized uptake value ratios (SUVR) (R2 = 0.997 using cerebellum as reference region and 0.996 using the pons). Our method allows for robust and accurate registration of [18F]florbetaben images to template space, without the need for an MR image, and may prove of value in clinical and research settings.
Collapse
Affiliation(s)
- Antoine Leuzy
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund UniversityMalmö, Sweden
| | | | | | | | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund UniversityMalmö, Sweden
- Memory Clinic, Skåne University HospitalLund, Sweden
| | - Johan Lilja
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund UniversityMalmö, Sweden
- Hermes Medical SolutionsStockholm, Sweden
- Department of Surgical Sciences, Nuclear Medicine and PET, Uppsala UniversityUppsala, Sweden
| |
Collapse
|
22
|
Park SY, Na SJ, Kumar M, Mosci C, Wardak M, Koglin N, Bullich S, Mueller A, Berndt M, Stephens AW, Cho YM, Ahn H, Chae SY, Kim HO, Moon DH, Gambhir SS, Mittra ES. Clinical Evaluation of (4S)-4-(3-[ 18F]Fluoropropyl)-L-glutamate ( 18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer. Clin Cancer Res 2020; 26:5380-5387. [PMID: 32694158 DOI: 10.1158/1078-0432.ccr-20-0644] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 05/25/2020] [Accepted: 07/14/2020] [Indexed: 12/24/2022]
Abstract
PURPOSE (4S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a radiopharmaceutical for PET imaging of system xC - activity, which can be upregulated in prostate cancer. We present data on the first evaluation of patients with newly diagnosed or recurrent prostate cancer with this radiopharmaceutical. EXPERIMENTAL DESIGN Ten patients with primary and 10 patients with recurrent prostate cancer were enrolled in this prospective multicenter study. After injection of 300 MBq of 18F-FSPG, three whole-body PET/CT scans were obtained. Visual analysis was compared with step-section histopathology when available as well as other imaging studies and clinical outcomes. Metabolic parameters were measured semiquantitatively. Expression levels of xCT and CD44 were evaluated by IHC for patients with available tissue samples. RESULTS 18F-FSPG PET showed high tumor-to-background ratios with a relatively high tumor detection rate on a per-patient (89%) and per-lobe (87%) basis. The sensitivity was slightly higher with imaging at 105 minutes in comparison with 60 minutes. The maximum standardized uptake values (SUVmax) for cancer was significantly higher than both normal (P < 0.005) and benign pathology (P = 0.011), while there was no significant difference between normal and benign pathology (P = 0.120). In the setting of recurrence, agreement with standard imaging was demonstrated in 7 of 9 patients (78%) and 13 of 18 lesions (72%), and revealed true local recurrence in a discordant case. 18F-FSPG accumulation showed moderate correlation with CD44 expression. CONCLUSIONS 18F-FSPG is a promising tumor imaging agent for PET that seems to have favorable biodistribution and high cancer detection rate in patients with prostate cancer. Further studies are warranted to determine the diagnostic value for both initial staging and recurrence, and how it compares with other investigational radiotracers and conventional imaging modalities.
Collapse
Affiliation(s)
- Sonya Youngju Park
- Department of Radiology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea (South).,Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California
| | - Sae Jung Na
- Department of Radiology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea (South).,Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea (South)
| | - Meena Kumar
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California
| | - Camila Mosci
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California
| | - Mirwais Wardak
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California
| | | | | | | | | | | | - Yong Mee Cho
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea (South)
| | - Hanjong Ahn
- Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea (South)
| | - Sun Young Chae
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea (South)
| | - Hye Ok Kim
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea (South).,Department of Nuclear Medicine, Ewha Woman's University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea (South)
| | - Dae Hyuk Moon
- Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea (South)
| | - Sanjiv S Gambhir
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California.,Department of Bioengineering, Department of Materials Science & Engineering, Stanford Bio-X Program, Stanford University, Stanford, California
| | - Erik S Mittra
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, California. .,Department of Diagnostic Radiology, Oregon Health & Science University, Portland, Oregon
| |
Collapse
|
23
|
Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, Perrotin A, Koglin N, Kroth H, Pfeifer A, Tamagnan G, Seibyl JP, Marek K, De Santi S, Dinkelborg LM, Stephens AW. Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. J Nucl Med 2019; 61:911-919. [PMID: 31712323 DOI: 10.2967/jnumed.119.236224] [Citation(s) in RCA: 77] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Accepted: 11/04/2019] [Indexed: 12/15/2022] Open
Abstract
18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, 18F-PI-2620 binds to both 3-repeat and 4-repeat tau isoforms. The purpose of this first-in-humans study was to evaluate the ability of 18F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerability of this new tau PET tracer. Methods: Participants with a clinical diagnosis of probable AD and healthy controls (HCs) underwent dynamic 18F-PI-2620 PET imaging for 180 min. 18F-PI-2620 binding was assessed visually and quantitatively using distribution volume ratios (DVR) estimated from noninvasive tracer kinetics and SUV ratio (SUVR) measured at different time points after injection, with the cerebellar cortex as the reference region. Time-activity curves and SUVR were assessed in AD and HC subjects, as well as DVR and SUVR correlations and effect size (Cohen's d) over time. Results: 18F-PI-2620 showed peak brain uptake around 5 min after injection and fast washout from nontarget regions. In AD subjects, focal asymmetric uptake was evident in temporal and parietal lobes, precuneus, and posterior cingulate cortex. DVR and SUVR in these regions were significantly higher in AD subjects than in HCs. Very low background signal was observed in HCs. 18F-PI-2620 administration was safe and well tolerated. SUVR time-activity curves in most regions and subjects achieved a secular equilibrium after 40 min after injection. A strong correlation (R 2 > 0.93) was found between noninvasive DVR and SUVR for all imaging windows starting at more than 30 min after injection. Similar effect sizes between AD and HC groups were obtained across the different imaging windows. 18F-PI-2620 uptake in neocortical regions significantly correlated with the degree of cognitive impairment. Conclusion: Initial clinical data obtained in AD and HC subjects demonstrated a high image quality and excellent signal-to-noise ratio of 18F-PI-2620 PET for imaging tau deposition in AD subjects. Noninvasive quantification using DVR and SUVR for 30-min imaging windows between 30 and 90 min after injection-for example, 45-75 min-provides robust and significant discrimination between AD and HC subjects. 18F-PI-2620 uptake in expected regions correlates strongly with neurocognitive performance.
Collapse
Affiliation(s)
| | | | | | | | | | - Caroline Papin
- Life Molecular Imaging GmbH, Berlin, Germany.,Invicro, New Haven, Connecticut
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Bullich S, Barret O, Constantinescu C, Sandiego C, Mueller A, Berndt M, Papin C, Perrotin A, Koglin N, Kroth H, Pfeifer A, Tamagnan G, Madonia J, Seibyl JP, Marek K, De Santi S, Dinkelborg LM, Stephens AW. Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of 18F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain. J Nucl Med 2019; 61:920-927. [PMID: 31712324 DOI: 10.2967/jnumed.119.236240] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Accepted: 11/04/2019] [Indexed: 02/01/2023] Open
Abstract
18F-PI-2620 is a next-generation tau PET tracer that has demonstrated ability to image the spatial distribution of suspected tau pathology. The objective of this study was to assess the tracer biodistribution, dosimetry, and quantitative methods of 18F-PI-2620 in the human brain. Full kinetic modeling to quantify tau load was investigated. Noninvasive kinetic modeling and semiquantitative methods were evaluated against the full tracer kinetics. Finally, the reproducibility of PET measurements from test and retest scans was assessed. Methods: Three healthy controls (HCs) and 4 Alzheimer disease (AD) subjects underwent 2 dynamic PET scans, including arterial sampling. Distribution volume ratio (DVR) was estimated using full tracer kinetics (reversible 2-tissue-compartment [2TC] model and Logan graphical analysis [LGA]) and noninvasive kinetic models (noninvasive LGA [NI-LGA] and the multilinear reference tissue model [MRTM2]). SUV ratio (SUVR) was determined at different imaging windows after injection. The correlation between DVR and SUVR, effect size (Cohen's d), and test-retest variability (TRV) were evaluated. Additionally, 6 HCs received 1 tracer administration and underwent whole-body PET for dosimetry calculation. Organ doses and the whole-body effective dose were calculated using OLINDA 2.0. Results: A strong correlation was found across different kinetic models (R 2 > 0.97) and between DVR(2TC) and SUVR between 30 and 90 min, with an R 2 of more than 0.95. Secular equilibrium was reached at around 40 min after injection in most regions and subjects. TRV and effect size for SUVR across different regions were similar at 30-60 min (TRV, 3.8%; Cohen's d, 3.80), 45-75 min (TRV, 4.3%; Cohen's d, 3.77) and 60-90 min (TRV, 4.9%; Cohen's d, 3.73) and increased at later time points. Elimination was via the hepatobiliary and urinary systems. The whole-body effective dose was 33.3 ± 2.1 μSv/MBq for an adult female and 33.1 ± 1.4 μSv/MBq for an adult male, with a 1.5-h urinary bladder voiding interval. Conclusion: 18F-PI-2620 exhibits fast kinetics, suitable dosimetry, and low TRV. DVR measured using the 2TC model with arterial sampling correlated strongly with DVR measured by NI-LGA, MRTM2, and SUVR. SUVR can be used for 18F-PI-2620 PET quantification of tau deposits, avoiding arterial blood sampling. Static 18F-PI-2620 PET scans between 45 and 75 min after injection provide excellent quantification accuracy, a large effect size, and low TRV.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Caroline Papin
- Life Molecular Imaging GmbH, Berlin, Germany.,Invicro, New Haven, Connecticut
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Stephens AW, Bullich S, Mueller A, Berndt M, de Santi S, Scott D, Adamczuk K, Suhy J, Kaplow J, Krause S, Chang J, Albala B, Luthman J. O4-12-05: EVALUATION OF TAU DEPOSITION IN AMYLOID-POSITIVE MCI OR MILD AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [ 18
F]PI-2620 PET. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.4810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL ® approaches: Validation against histopathology. Alzheimers Dement 2019; 15:807-816. [PMID: 31101517 DOI: 10.1016/j.jalz.2019.02.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 02/15/2019] [Accepted: 02/25/2019] [Indexed: 01/22/2023]
Abstract
INTRODUCTION 18F-florbetaben is currently approved for the visual rule out of β-amyloid (Aβ) pathology. It is also used for recruitment and as an outcome measure in therapeutic trials, requiring accurate and reproducible quantification of Aβ burden in the brain. METHODS Data from eighty-eight subjects (52 male subjects, aged 79.8 ± 10.6 years) who underwent antemortem 18F-florbetaben positron emission tomography scan and magnetic resonance imaging less than a year before neuropathological assessment at autopsy were evaluated. Image analysis was performed using the standard Centiloid (CL) statistical parametric mapping approach and CapAIBL®. Imaging results were compared against autopsy data. RESULTS Against combined Bielschowsky silver staining and immunohistochemistry histopathological scores, statistical parametric mapping had 96% sensitivity, 96% specificity, and 95% accuracy, whereas magnetic resonance-less CapAIBL standardized uptake value ratioWhole Cerebellum had 94% sensitivity, 96% specificity, and 95% accuracy. Based on the combined histopathological scores, a CL threshold band of 19 ± 7 CL was determined. DISCUSSION Quantification of 18F-florbetaben positron emission tomography scans using magnetic resonance-based and magnetic resonance-less CapAIBL® approaches showed high agreement, establishing a pathology-based threshold in CL.
Collapse
Affiliation(s)
- Vincent Doré
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia.
| | | | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Salamata Konate
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Osama Sabri
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | | | - Henryk Barthel
- Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany
| | - Jurgen Fripp
- CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Colin L Masters
- The Florey Institute of Neurosciences and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | | | - Olivier Salvado
- CSIRO Health and Biosecurity Flagship: The Australian e-Health Research Centre, Brisbane, QLD, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | | |
Collapse
|
27
|
Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA. Optimized dual-time-window protocols for quantitative [ 18F]flutemetamol and [ 18F]florbetaben PET studies. EJNMMI Res 2019; 9:32. [PMID: 30919133 PMCID: PMC6437225 DOI: 10.1186/s13550-019-0499-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Accepted: 03/11/2019] [Indexed: 12/12/2022] Open
Abstract
Background A long dynamic scanning protocol may be required to accurately measure longitudinal changes in amyloid load. However, such a protocol results in a lower patient comfort and scanning efficiency compared to static scans. A compromise can be achieved by implementing dual-time-window protocols. This study aimed to optimize these protocols for quantitative [18F]flutemetamol and [18F]florbetaben studies. Methods Rate constants for subjects across the Alzheimer’s disease spectrum (i.e., non-displaceable binding potential (BPND) in the range 0.02–0.77 and 0.02–1.04 for [18F]flutemetamol and [18F]florbetaben, respectively) were established based on clinical [18F]flutemetamol (N = 6) and [18F]florbetaben (N = 20) data, and used to simulate tissue time-activity curves (TACs) of 110 min using a reference tissue and plasma input model. Next, noise was added (N = 50) and data points corresponding to different intervals were removed from the TACs, ranging from 0 (i.e., 90–90 = full-kinetic curve) to 80 (i.e., 10–90) minutes, creating a dual-time-window. Resulting TACs were fitted using the simplified reference tissue method (SRTM) to estimate the BPND, outliers (≥ 1.5 × BPND max) were removed and the bias was assessed using the distribution volume ratio (DVR = BPND + 1). To this end, acceptability curves, which display the fraction of data below a certain bias threshold, were generated and the area under those curves were calculated. Results [18F]Flutemetamol and [18F]florbetaben data demonstrated an increased bias in amyloid estimate for larger intervals and higher noise levels. An acceptable bias (≤ 3.1%) in DVR could be obtained with all except the 10–90 and 20–90-min intervals. Furthermore, a reduced fraction of acceptable data and most outliers were present for these two largest intervals (maximum percentage outliers 48 and 32 for [18F]flutemetamol and [18F]florbetaben, respectively). Conclusions The length of the interval inversely correlates with the accuracy of the BPND estimates. Consequently, a dual-time-window protocol of 0–30 and 90–110 min (=maximum of 60 min interval) allows for accurate estimation of BPND values for both tracers. [18F]flutemetamol: EudraCT 2007-000784-19, registered 8 February 2007, [18F]florbetaben: EudraCT 2006-003882-15, registered 2006. Electronic supplementary material The online version of this article (10.1186/s13550-019-0499-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Fiona Heeman
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands.
| | - Maqsood Yaqub
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands
| | - Isadora Lopes Alves
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands
| | - Kerstin Heurling
- Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, 405 30, Gothenburg, Sweden
| | - Johannes Berkhof
- Amsterdam UMC, Vrije Universiteit Amsterdam, Epidemiology and Biostatistics, De Boelelaan, 1117, Amsterdam, Netherlands
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Carrer de Wellington, 30, 08005, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, 28029, Madrid, Spain.,Universitat Pompeu Fabra, Plaça de la Mercè, 10, 08002, Barcelona, Spain
| | - Santiago Bullich
- Life Molecular Imaging GmbH, Tegeler Str. 7, 13353, Berlin, Germany
| | | | - Adriaan A Lammertsma
- Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan, 1117, Amsterdam, Netherlands
| | | |
Collapse
|
28
|
Boada M, Rodriguez-Gomez O, Gil S, Sanabria A, Alegret M, Moreno-Grau S, Perez A, Lomeña F, Pavía J, Gismondi R, Bullich S, Vivas A, Chiari MG, Páez A, Núñez L, Hernández-Olasagarre B, Orellana A, Valero S, Ruiz AR, Tarraga L, Monté-Rubio G. P1‐428: APOE STATUS MODULATES BRAIN PATTERNS OF AMYLOID DISTRIBUTION IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE (SCD) FROM THE FACEHBI STUDY. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Mercè Boada
- Fundació ACEBarcelona Alzheimer Treatment & Research CenterBarcelonaSpain
| | | | - Silvia Gil
- Fundació ACEBarcelona Alzheimer Treatment & Research CenterBarcelonaSpain
| | - Angela Sanabria
- Fundació ACEBarcelona Alzheimer Treatment & Research CenterBarcelonaSpain
| | - Montserrat Alegret
- Fundació ACEBarcelona Alzheimer Treatment & Research CenterBarcelonaSpain
| | - Sonia Moreno-Grau
- Neuroscience CenterFundació ACE, Institut Català de Neurociències AplicadesBarcelonaSpain
| | - Alba Perez
- Fundació ACEBarcelona Alzheimer Treatment & Research CenterBarcelonaSpain
| | | | - Javier Pavía
- Nuclear Medicine DepartmentHospital ClinicBarcelonaSpain
| | | | | | | | | | | | | | | | - Adelina Orellana
- Neuroscience CenterFundació ACE, Institut Català de Neurociències AplicadesBarcelonaSpain
| | - Sergi Valero
- Neuroscience CenterFundació ACE, Institut Català de Neurociències AplicadesBarcelonaSpain
| | - Agustín Ruiz Ruiz
- Neuroscience CenterFundació ACE, Institut Català de Neurociències AplicadesBarcelonaSpain
| | - Lluis Tarraga
- Fundació ACEBarcelona Alzheimer Treatment & Research CenterBarcelonaSpain
| | - Gemma Monté-Rubio
- Neuroscience CenterFundació ACE, Institut Català de Neurociències AplicadesBarcelonaSpain
| |
Collapse
|
29
|
Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, Stephens AW, Sabri O. Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol. J Nucl Med 2017; 59:1104-1110. [PMID: 29175981 DOI: 10.2967/jnumed.117.200964] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Accepted: 11/10/2017] [Indexed: 11/16/2022] Open
Abstract
Accurate amyloid PET quantification is necessary for monitoring amyloid-β accumulation and response to therapy. Currently, most of the studies are analyzed using the static SUV ratio (SUVR) approach because of its simplicity. However, this approach may be influenced by changes in cerebral blood flow (CBF) or radiotracer clearance. Full tracer kinetic models require arterial blood sampling and dynamic image acquisition. The objectives of this work were, first, to validate a noninvasive kinetic modeling approach for 18F-florbetaben PET using an acquisition protocol with the best compromise between quantification accuracy and simplicity and, second, to assess the impact of CBF changes and radiotracer clearance on SUVRs and noninvasive kinetic modeling data in 18F-florbetaben PET. Methods: Using data from 20 subjects (10 patients with probable Alzheimer dementia and 10 healthy volunteers), the nondisplaceable binding potential (BPND) obtained from the full kinetic analysis was compared with the SUVR and with noninvasive tracer kinetic methods (simplified reference tissue model and multilinear reference tissue model 2). Various approaches using shortened or interrupted acquisitions were compared with the results of the full acquisition (0-140 min). Simulations were performed to assess the effect of CBF and radiotracer clearance changes on SUVRs and noninvasive kinetic modeling outputs. Results: An acquisition protocol using time windows of 0-30 and 120-140 min with appropriate interpolation of the missing time points provided the best compromise between patient comfort and quantification accuracy. Excellent agreement was found between BPND obtained using the full protocol and BPND obtained using the dual-window protocol (for multilinear reference tissue model 2, BPND [dual-window] = 0.01 + 1.00·BPND [full], R2 = 0.97; for simplified reference tissue model, BPND [dual-window] = 0.05 + 0.92·BPND [full], R2 = 0.93). Simulations showed a limited impact of CBF and radiotracer clearance changes on multilinear reference tissue model parameters and SUVR. Conclusion: This study demonstrated accurate noninvasive kinetic modeling of 18F-florbetaben PET data using a dual-window acquisition, thus providing a good compromise between quantification accuracy, scan duration, and patient burden. The influence of CBF and radiotracer clearance changes on amyloid-β load estimates was small. For most clinical research applications, the SUVR approach is appropriate. However, for longitudinal studies in which maximum quantification accuracy is desired, this noninvasive dual-window acquisition with kinetic analysis is recommended.
Collapse
Affiliation(s)
| | - Henryk Barthel
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and
| | | | - Georg A Becker
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and
| | | | | | | | - Osama Sabri
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and
| |
Collapse
|
30
|
Ceccaldi M, Jonveaux T, Verger A, Krolak‐Salmon P, Houzard C, Godefroy O, Shields T, Perrotin A, Gismondi R, Bullich S, Jovalekic A, Raffa N, Pasquier F, Semah F, Dubois B, Habert M, Wallon D, Chastan M, Payoux P, Ceccaldi M, Guedj E, Ceccaldi M, Felician O, Didic M, Gueriot C, Koric L, Kletchkova‐Gantchev R, Guedj E, Godefroy O, Andriuta D, Devendeville A, Dupuis D, Binot I, Barbay M, Meyer M, Moullard V, Magnin E, Chamard L, Haffen S, Morel O, Drouet C, Boulahdour H, Goas P, Querellou‐Lefranc S, Sayette V, Cogez J, Branger P, Agostini D, Manrique A, Rouaud O, Bejot Y, Jacquin‐Piques A, Dygai‐Cochet I, Berriolo‐Riedinger A, Moreaud O, Sauvee M, Crépin CG, Pasquier F, Bombois S, Lebouvier T, Mackowiak‐Cordoliani M, Deramecourt V, Rollin‐Sillaire A, Cassagnaud‐Thuillet P, Chen Y, Semah F, Petyt G, Krolak‐Salmon P, Federico D, Danaila KL, Guilhermet Y, Magnier C, Makaroff Z, Rouch I, Xie J, Roubaud C, Coste M, David K, Sarciron A, Waissi AS, Scheiber C, Houzard C, Gabelle‐Deloustal A, Bennys K, Marelli C, Touati L, Mariano‐Goulart D, Verbizier‐Lonjon D, Jonveaux T, Benetos A, Kearney‐Schwartz A, Perret‐Guillaume C, Verger A, Vercelletto M, Boutoleau‐Bretonniere C, Pouclet‐Courtemanche H, Wagemann N, Pallardy A, Hugon J, Paquet C, Dumurgier J, Millet P, Queneau M, Dubois B, Epelbaum S, Levy M, Habert M, Novella J, Jaidi Y, Papathanassiou D, Morland D, Belliard S, Salmon A, Lejeune F, Hannequin D, Wallon D, Martinaud O, Zarea A, Chastan M, Pariente J, Thalamas C, Galitzky‐Gerber M, Tricoire Ricard A, Calvas F, Rigal E, Payoux P, Hitzel A, Delrieu J, Ousset P, Lala F, Sastre‐Hengan N, Stephens A, Guedj E. Added value of
18
F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimers Dement 2017; 14:293-305. [DOI: 10.1016/j.jalz.2017.09.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 08/29/2017] [Accepted: 09/06/2017] [Indexed: 11/25/2022]
Affiliation(s)
- Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thérèse Jonveaux
- Geriatric Department CHRU de Nancy–Hôpital Brabois Vandoeuvre‐les‐Nancy France
| | - Antoine Verger
- INSERM U947 Unité d'Imagerie Adaptative Diagnostique et Interventionnelle Nancy France
| | - Pierre Krolak‐Salmon
- Clinical and Research Memory Center of Lyon Hospices civils de Lyon, Université Claude Bernard Lyon 1 Inserm 1028 Lyon France
| | | | - Olivier Godefroy
- Neurology Department CHU Amiens Picardie–Hôpital Sud Amiens France
| | - Trevor Shields
- Nuclear Medicine Department CHU Amiens Picardie–Hôpital Sud Amiens France
| | - Audrey Perrotin
- Piramal Imaging Clinical Research and Development Berlin Germany
| | | | - Santiago Bullich
- AP‐HP–Hôpital Pitié Salpétrière Memory and Alzheimer Disease Institute IM2A Paris France
| | - Aleksandar Jovalekic
- Laboratoire d'Imagerie Biomédicale Sorbonne Universités, UPMC Univ Paris 06, Inserm U 1146, CNRS UMR 7371 Paris France
| | - Nicola Raffa
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Pasquier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Franck Semah
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Bruno Dubois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Odile Habert
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - David Wallon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Chastan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Payoux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Ceccaldi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Felician
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mira Didic
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claude Gueriot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Lejla Koric
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Radka Kletchkova‐Gantchev
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Godefroy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Daniela Andriuta
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Agnès Devendeville
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Diane Dupuis
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Ingrid Binot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mélanie Barbay
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marc‐Etienne Meyer
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Véronique Moullard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eloi Magnin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Ludivine Chamard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Sophie Haffen
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Morel
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Clément Drouet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Hatem Boulahdour
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Philippe Goas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Solène Querellou‐Lefranc
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Vincent Sayette
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Cogez
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Branger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Agostini
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alain Manrique
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Rouaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yannick Bejot
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Agnès Jacquin‐Piques
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Inna Dygai‐Cochet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alina Berriolo‐Riedinger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Moreaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathilde Sauvee
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Céline Gallazzani Crépin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Pasquier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Stéphanie Bombois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thibaud Lebouvier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Anne Mackowiak‐Cordoliani
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Vincent Deramecourt
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Adeline Rollin‐Sillaire
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pascaline Cassagnaud‐Thuillet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yaohua Chen
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Franck Semah
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Grégory Petyt
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pierre Krolak‐Salmon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Federico
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Keren Liora Danaila
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yves Guilhermet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christophe Magnier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Zaza Makaroff
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Isabelle Rouch
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Jing Xie
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Caroline Roubaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marie‐Hélène Coste
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Kenny David
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Alain Sarciron
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Aziza Sediq Waissi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christian Scheiber
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Houzard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Audrey Gabelle‐Deloustal
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Karim Bennys
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Cecilia Marelli
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Lynda Touati
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Denis Mariano‐Goulart
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Delphine Verbizier‐Lonjon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Thérèse Jonveaux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Athanase Benetos
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anna Kearney‐Schwartz
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Christine Perret‐Guillaume
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Antoine Verger
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Martine Vercelletto
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Boutoleau‐Bretonniere
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Hélène Pouclet‐Courtemanche
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Nathalie Wagemann
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Amandine Pallardy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Jacques Hugon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Claire Paquet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Dumurgier
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Pascal Millet
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Queneau
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Bruno Dubois
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Stéphane Epelbaum
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Marcel Levy
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Jean‐Luc Novella
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Yacine Jaidi
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Dimitri Papathanassiou
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Serge Belliard
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anne Salmon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Florence Lejeune
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Didier Hannequin
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - David Wallon
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Olivier Martinaud
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Aline Zarea
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Mathieu Chastan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | - Claire Thalamas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | | | | | - Fabienne Calvas
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Emilie Rigal
- ToNIC, Toulouse NeuroImaging Center Université de Toulouse, Inserm, UPS Toulouse France
| | - Pierre Payoux
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Anne Hitzel
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Julien Delrieu
- Neurology Department CHU de Rouen–Hôpital Charles Nicolle Rouen France
| | - Pierre‐Jean Ousset
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Françoise Lala
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Nathalie Sastre‐Hengan
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Andrew Stephens
- AP‐HM–Hôpital de la Timone, Neurology and Neuropsychology Department Aix Marseille University, Inserm, INS, Institut de Neurosciences des Systèmes Marseille France
| | - Eric Guedj
- AP‐HM–Hôpital de la Timone, Nuclear Medicine Department Aix‐Marseille University, CERIMED, CNRS, INT, Institut de Neurosciences de la Timone Marseille France
| | | |
Collapse
|
31
|
Catafau AM, Bullich S. Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation. Curr Alzheimer Res 2017; 14:169-177. [PMID: 27334945 DOI: 10.2174/1567205013666160620111408] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2016] [Revised: 06/26/2016] [Accepted: 06/27/2016] [Indexed: 11/22/2022]
Abstract
Clinical classifications of neurodegenerative disorders are often based on neuropathology. The term "proteinopathies" includes disorders that have in common abnormal proteins as a hallmark, e.g. amyloidoses, tauopathies, synucleopathies, ubiquitinopathies. Different proteins can also co-exist in the same disease. To further complicate the pathophysiology scenario, not only different proteins, but also cells are believed to play an active role in neurodegeneration, in particular those participating in neuroinflammatory processes in the brain, such as activated microglia and astrocytes. In clinical practice, differentiating pathophysiology from clinical symptoms to allow accurate clinical classification of these disorders during life, becomes difficult in absence of biomarkers for these pathology hallmarks. PET imaging can be a useful tool in this context. Using PET tracers targeting misfolded proteins it will be possible to identify the presence or absence of the target, to depict the cerebral distribution and to quantify the protein load in different cerebral regions, as well as to monitor changes over time. Beta-amyloid is one of the proteins involved in neurodegenerative disorders, which is currently suitable to be imaged by means of PET. Research efforts are currently ongoing in order to identify new PET tracers targeting non-amyloid PET tracers for neurodegeneration. This article will focus on the investigational PET tracers targeting tau and alpha-synuclein as misfolded proteins, and activated microglia and astrocytes as cellular targets for neuroinflammation. An overview of target characteristics, development challenges, clinical relevance and current status of human PET imaging is provided.
Collapse
|
32
|
Schipke CG, Koglin N, Bullich S, Joachim LK, Haas B, Seibyl J, Barthel H, Sabri O, Peters O. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid. Psychiatry Res Neuroimaging 2017; 265:98-101. [PMID: 28024844 DOI: 10.1016/j.pscychresns.2016.10.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 10/27/2016] [Accepted: 10/28/2016] [Indexed: 01/26/2023]
Abstract
Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer's disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET signal of the 18F-labelled tracer florbetaben (NeuraCeq™), that binds to amyloid-beta plaques, inversely correlates with CSF levels of Aß42, another biomarker for AD. Results from the two biomarkers were concordant in 35 out of 38 subjects. In 7 AD subjects (20%) at least one biomarker was inconsistent with the clinical diagnosis. This confirms known limitations of the clinical AD diagnosis and highlights the potential of biomarker-assisted diagnosis to improve accuracy.
Collapse
Affiliation(s)
- Carola G Schipke
- Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Charité-Universitätsmedizin Berlin, Institute of Neuropathology, Berlin, Germany.
| | | | | | | | - Brigitte Haas
- Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Department of Psychiatry, Charité-Campus Benjamin Franklin, Berlin, Germany
| | - John Seibyl
- Molecular NeuroImaging, LLC (MNI), New Haven, CT, USA
| | - Henryk Barthel
- Leipzig University, Department of Nuclear Medicine, Leipzig, Germany
| | - Osama Sabri
- Leipzig University, Department of Nuclear Medicine, Leipzig, Germany
| | - Oliver Peters
- Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Department of Psychiatry, Charité-Campus Benjamin Franklin, Berlin, Germany
| |
Collapse
|
33
|
Dore V, Bullich S, Rowe CC, Bourgeat P, Konate S, Stephens A, Fripp J, Masters CL, Salvado O, Villemagne VL, Santi S. [IC‐P‐162]: COMPARISON OF
18
F‐FLORBETABEN QUANTIFICATION RESULTS USING MR‐BASED AND MR‐LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Vincent Dore
- CSIROMelbourneAustralia
- Austin HealthMelbourneAustralia
| | | | - Christopher C. Rowe
- Austin HealthMelbourneAustralia
- AIBL Research GroupPerth and MelbourneAustralia
- The University of MelbourneParkvilleAustralia
| | | | | | | | | | - Colin L. Masters
- AIBL Research GroupPerth and MelbourneAustralia
- The Florey Institute of Neuroscience and Mental HealthParkvilleAustralia
| | - Olivier Salvado
- Commonwealth Scientific and Industrial Research OrganisationBrisbaneAustralia
| | - Victor L. Villemagne
- Austin HealthMelbourneAustralia
- AIBL Research GroupPerth and MelbourneAustralia
- The Florey Institute of Neuroscience and Mental HealthMelbourneAustralia
| | | |
Collapse
|
34
|
Gispert JD, Foley C, Lammertsma AA, Berckel BN, Yaqub MM, Cardoso MJ, Markiewicz P, Modat M, Buckley CJ, Mett A, Bullich S, Banton N, Grecci E, Hall J, Hill DL, Payoux P, Drzezga A, Ritchie CW, Schmidt ME, Farrar G, Barkhof F. [P2–418]: METHODOLOGICAL AND LOGISTIC STRATEGIES FOR A LARGE MULTI‐CENTER β‐AMYLOID PET EUROPEAN PROJECT: AMYLOID IMAGING TO PREVENT ALZHEIMER's DISEASE (AMYPAD). Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | | | | | - Bart N.M. Berckel
- Department of Radiology and Nuclear Medicine, Amsterdam NeuroscienceVU University Medical CenterAmsterdamNetherlands
| | - Maqsood M. Yaqub
- Department of Radiology & Nuclear MedicineVU University Medical CenterAmsterdamNetherlands
| | - M. Jorge Cardoso
- Translational Imaging Group, Centre for Medical Image ComputingDepartment of Medical Physics and Biomedical Engineering, UCLLondonUnited Kingdom
| | - Pawel Markiewicz
- Translational Imaging Group, UCL Centre for Medial Image ComputingLondonUnited Kingdom
| | - Marc Modat
- Translational Imaging Group, Centre for Medical Image ComputingDepartment of Medical Physics and Biomedical Engineering, UCLLondonUnited Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, Amsterdam NeuroscienceVU University Medical CenterAmsterdamNetherlands
- Translational Imaging GroupCentre for Medical Image ComputingUniversity College LondonLondonUnited Kingdom
| |
Collapse
|
35
|
Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, Sabri O, De Santi S. Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. Neuroimage Clin 2017; 15:325-332. [PMID: 28560157 PMCID: PMC5440277 DOI: 10.1016/j.nicl.2017.04.025] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 04/24/2017] [Accepted: 04/25/2017] [Indexed: 11/28/2022]
Abstract
Introduction Standardized uptake value ratios (SUVRs) calculated from cerebral cortical areas can be used to categorize 18F-Florbetaben (FBB) PET scans by applying appropriate cutoffs. The objective of this work was first to generate FBB SUVR cutoffs using visual assessment (VA) as standard of truth (SoT) for a number of reference regions (RR) (cerebellar gray matter (GCER), whole cerebellum (WCER), pons (PONS), and subcortical white matter (SWM)). Secondly, to validate the FBB PET scan categorization performed by SUVR cutoffs against the categorization made by post-mortem histopathological confirmation of the Aβ presence. Finally, to evaluate the added value of SUVR cutoff categorization to VA. Methods SUVR cutoffs were generated for each RR using FBB scans from 143 subjects who were visually assessed by 3 readers. SUVR cutoffs were validated in 78 end-of life subjects using VA from 8 independent blinded readers (3 expert readers and 5 non-expert readers) and histopathological confirmation of the presence of neuritic beta-amyloid plaques as SoT. Finally, the number of correctly or incorrectly classified scans according to pathology results using VA and SUVR cutoffs was compared. Results Composite SUVR cutoffs generated were 1.43 (GCER), 0.96 (WCER), 0.78 (PONS) and 0.71 (SWM). Accuracy values were high and consistent across RR (range 83–94% for histopathology, and 85–94% for VA). SUVR cutoff performed similarly as VA but did not improve VA classification of FBB scans read either by expert readers or the majority read but provided higher accuracy than some non-expert readers. Conclusion The accurate scan classification obtained in this study supports the use of VA as SoT to generate site-specific SUVR cutoffs. For an elderly end of life population, VA and SUVR cutoff categorization perform similarly in classifying FBB scans as Aβ-positive or Aβ-negative. These results emphasize the additional contribution that SUVR cutoff classification may have compared with VA performed by non-expert readers. SUVR cutoffs to classify Florbetaben PET scans as positive and negative were generated. SUVR cutoffs were validated against post-mortem histopathological confirmation. Added value of SUVR cutoff classification to visual assessment was evaluated. SUVR cutoff classification provided higher accuracy than some non-expert readers. Results emphasize the contribution that SUVR cutoffs may have to visual assessment.
Collapse
Affiliation(s)
| | | | | | | | | | - Henryk Barthel
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | - Osama Sabri
- Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
| | | |
Collapse
|
36
|
Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, De Santi S. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with 18F-Florbetaben PET. J Nucl Med 2017; 58:1300-1306. [PMID: 28183994 DOI: 10.2967/jnumed.116.187351] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 01/05/2017] [Indexed: 12/24/2022] Open
Abstract
Accurate measurement of changes in amyloid-β (Aβ) deposition over time is important in longitudinal studies, particularly in anti-Aβ therapeutic trials. To achieve this, the optimal reference region (RR) must be selected to reduce variance of Aβ PET measurements, allowing early detection of treatment efficacy. The aim of this study was to determine the RR that allows earlier detection of subtle Aβ changes using 18F-florbetaben PET. Methods: Forty-five patients with mild cognitive impairment (mean age ± SD, 72.69 ± 6.54 y; 29 men/16 women) who underwent up to 3 18F-florbetaben scans were included. Baseline scans were visually classified as high (Aβ+) or low (Aβ-) amyloid. Six cortical regions were quantified using a standardized region-of-interest atlas applied to the spatially normalized gray matter image obtained from segmentation of the baseline T1-weighted volumetric MRI. Four RRs (cerebellar gray matter [CGM], whole cerebellum [WCER], pons, and subcortical white matter [SWM]) were studied. The SUV ratio (SUVR) for each RR was calculated by dividing cortex activity by RR activity, with a composite SUVR averaged over 6 cortical regions. SUVR increase from baseline to 1 and 2 y, and percentage Aβ deposition per year, were assessed across Aβ+ and Aβ- groups. Results: SUVs for any RR were not significantly different over time. Percentage Aβ accumulation per year derived from composite SUVR was 0.10 ± 1.72 (Aβ-) and 1.36 ± 1.98 (Aβ+) (P = 0.02) for CGM and 0.13 ± 1.47 and 1.32 ± 1.75 (P = 0.01), respectively, for WCER. Compared with baseline, the composite SUVR increase in Aβ+ scans was significantly larger than in Aβ- scans at 1 y (P = 0.04 [CGM]; P = 0.03 [WCER]) and 2 y (P = 0.02 [CGM]; P = 0.01 [WCER]) using these 2 RRs. Significant SUVR changes using the pons as the RR were detected only at 2 y (P = 0.46 [1 y], P = 0.001 [2 y]). SUVR using the SWM as the RR showed no significant differences at either follow-up (P = 0.39 [1 y], P = 0.09 [2 y]). Conclusion: RR selection influences reliable early measurement of Aβ changes over time. Compared with SWM and pons, which do not fulfil the RR requirements and have limited sensitivity to detect Aβ changes, cerebellar RRs are recommended for 18F-florbetaben PET because they allow earlier detection of Aβ accumulation.
Collapse
Affiliation(s)
| | - Victor L Villemagne
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health, Melbourne, Victoria, Australia; and
| | | | | | | | - Christopher C Rowe
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health, Melbourne, Victoria, Australia; and
| | | |
Collapse
|
37
|
Jovalekic A, Bullich S, Catafau A, de Santi S. Advances in Aβ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease. Neurodegener Dis Manag 2016; 6:491-497. [PMID: 27813444 DOI: 10.2217/nmt-2016-0026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Clinical diagnosis of Alzheimer's disease (AD) can be challenging as numerous diseases mimic the characteristics of AD. In this light, recent guidelines developed by different associations and working groups point out the need for biomarkers to support AD diagnosis. This paper discusses 18F-labeled radiotracers (which are indicated for PET imaging of the brain) and ongoing clinical studies that aim to generate new evidence for the usage of amyloid imaging. In addition to their relatively long half-life, these agents are known for their high sensitivity and high negative predictive values for detection of neuritic Aβ plaques. Comparisons with other biomarkers are provided and implications of diagnostic disclosures discussed. Finally, recent data from clinical trials underscore the importance of amyloid PET for detecting, quantifying and monitoring Aβ plaque deposits.
Collapse
Affiliation(s)
| | | | - Ana Catafau
- formerly Piramal Imaging GmbH, Berlin, Germany
| | | |
Collapse
|
38
|
López-Vilanova N, Pavía J, Duch MA, Catafau A, Ros D, Bullich S. Impact of Region-of-Interest Delineation Methods, Reconstruction Algorithms, and Intra- and Inter-Operator Variability on Internal Dosimetry Estimates Using PET. Mol Imaging Biol 2016; 19:305-314. [PMID: 27632424 DOI: 10.1007/s11307-016-1003-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE Human dosimetry studies play a central role in radioligand development for positron emission tomography (PET). Drawing regions of interest (ROIs) on the PET images is used to measure the dose in each organ. In the study aspects related to ROI delineation methods were evaluated for two radioligands of different biodistribution (intestinal vs urinary). PROCEDURES PET images were simulated from a human voxel-based phantom. Several ROI delineation methods were tested: antero-posterior projections (AP), 3D sub-samples of the organs (S), and a 3D volume covering the whole-organ (W). Inter- and intra-operator variability ROI drawing was evaluated by using human data. RESULTS The effective dose estimates using S and W methods were comparable to the true values. AP methods overestimated (49 %) the dose for the radioligand with intestinal biodistribution. Moreover, the AP method showed the highest inter-operator variability: 11 ± 1 %. CONCLUSIONS The sub-sampled organ method showed the best balance between quantitative accuracy and inter- and intra-operator variability.
Collapse
Affiliation(s)
- N López-Vilanova
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain. .,Institut de Tècniques Energètiques (INTE), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain.
| | - J Pavía
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain.,Nuclear Medicine Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - M A Duch
- Institut de Tècniques Energètiques (INTE), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - A Catafau
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Barcelona Imaging Group (BIG), Barcelona, Spain
| | - D Ros
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Unitat de Biofísica i Bioenginyeria, Universitat de Barcelona, Barcelona, Spain
| | - S Bullich
- Molecular Imaging Centre (CRC-CIM), Barcelona Biomedical Research Park, Barcelona, Spain
| |
Collapse
|
39
|
Bullich S, Catafau AM, Villemagne VL, Rowe CC, De Santi S. P2‐271: Optimal Reference Region to Measure Longitudinal Amyloid‐Beta Change with 18F‐Florbetaben Pet. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.1531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
| | | | - Victor L. Villemagne
- Department of Molecular Imaging and Therapy Centre for PET, Austin HealthHeidelbergAustralia
| | | | | |
Collapse
|
40
|
De Santi S, Catafau AM, Seibyl JP, Bullich S. IC‐P‐001: 18F‐Florbetaben Suvr Cutoff Quantification Across Reference Regions and Standards of Truth and Comparison to Visual Assessment. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
41
|
De Santi S, Catafau AM, Seibyl JP, Bullich S. P4‐164: 18F‐Florbetaben Suvr Cutoff Quantification Across Reference Regions and Standards of Truth and Comparison to Visual Assessment. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.2256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Bullich S, Catafau AM, Villemagne VL, Rowe CC, De Santi S. IC‐P‐003: Optimal Reference Region to Measure Longitudinal Amyloid‐Beta Change with 18F‐Florbetaben PET. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | | | - Victor L. Villemagne
- Department of Molecular Imaging and Therapy Centre for PET, Austin HealthHeidelbergAustralia
| | | | | |
Collapse
|
43
|
Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B, Leverenz J, Ironside JW, Schulz-Schaeffer WJ, Hoffmann A, Sabri O. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? J Nucl Med 2016; 57:1740-1745. [PMID: 27363836 DOI: 10.2967/jnumed.115.171652] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Accepted: 04/14/2016] [Indexed: 11/16/2022] Open
Abstract
SUV ratios (SUVRs) are used for relative quantification of 18F-florbetaben scans. The cerebellar cortex can be used as a reference region for quantification. However, cerebellar amyloid-β (Aβ) plaques may be present in Alzheimer disease (AD). The aim of this study was to assess the influence of Aβ pathology, including neuritic plaques, diffuse plaques, and vascular deposits, in 18F-florbetaben SUVR when cerebellum is used as the reference. METHODS Using immunohistochemistry to demonstrate Aβ plaques and vascular deposits, and using the Bielschowsky method to demonstrate neuritic plaques, we performed a neuropathologic assessment of the frontal, occipital, anterior cingulate, and posterior cingulate cerebral cortices and the cerebellar cortex of 87 end-of-life patients (64 with AD, 14 with other types of dementia, and 9 nondemented aged volunteers; mean age ± SD, 80.4 ± 10.2 y) who had undergone 18F-florbetaben PET before death. The lesions were rated as absent (none or sparse) or present (moderate or frequent). Mean cortical SUVRs were compared among cases with different cerebellar Aβ loads. RESULTS None of the 83 evaluable cerebellar samples showed frequent diffuse Aβ or neuritic plaques; 8 samples showed frequent vascular Aβ deposits. Diffuse Aβ plaques were rated as absent in 78 samples (94%) and present in 5 samples (6%). Vascular Aβ was rated as absent in 62 samples (74.7%) and present in 21 samples (25.3%). No significant differences in cerebellar SUVs were found among cases with different amounts or types of Aβ deposits in the cerebral cortex. Both diffuse and neuritic plaques were found in the cerebral cortex of 26-44 cases. No significant SUVR differences were found between these brains with different cerebellar Aβ loads. CONCLUSION The effect of cerebellar plaques on cortical 18F-florbetaben SUVRs appears to be negligible even in advanced stages of AD with a higher cerebellar Aβ load.
Collapse
Affiliation(s)
| | | | | | | | | | - James Leverenz
- VA-Puget Sound Health Care System and University of Washington, Seattle, Washington
| | | | | | | | | |
Collapse
|
44
|
Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Takao M, Akatsu H, Murayama S, Bullich S, Mueller A, Koglin N, Schulz-Schaeffer WJ, Hoffmann A, Sabbagh MN, Stephens AW, Sabri O. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study. J Nucl Med 2016; 57:900-6. [PMID: 26823561 DOI: 10.2967/jnumed.115.161927] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 01/04/2016] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED Training for accurate image interpretation is essential for the clinical use of β-amyloid PET imaging, but the role of interpreter training and the accuracy of the algorithm for routine visual assessment of florbetaben PET scans are unclear. The aim of this study was to test the robustness of the visual assessment method for florbetaben scans, comparing efficacy readouts across different interpreters and training methods and against a histopathology standard of truth (SoT). METHODS Analysis was based on data from an international open-label, nonrandomized, multicenter phase-3 study in patients with or without dementia (ClinicalTrials.gov: NCT01020838). Florbetaben scans were assessed visually and quantitatively, and results were compared with amyloid plaque scores. For visual assessment, either in-person training (n = 3 expert interpreters) or an electronic training method (n = 5 naïve interpreters) was used. Brain samples from participants who died during the study were used to determine the histopathologic SoT using Bielschowsky silver staining (BSS) and immunohistochemistry for β-amyloid plaques. RESULTS Data were available from 82 patients who died and underwent postmortem histopathology. When visual assessment results were compared with BSS + immunohistochemistry as SoT, median sensitivity was 98.2% for the in-person-trained interpreters and 96.4% for the e-trained interpreters, and median specificity was 92.3% and 88.5%, respectively. Median accuracy was 95.1% and 91.5%, respectively. On the basis of BSS only as the SoT, median sensitivity was 98.1% and 96.2%, respectively; median specificity was 80.0% and 76.7%, respectively; and median accuracy was 91.5% and 86.6%, respectively. Interinterpreter agreement (Fleiss κ) was excellent (0.89) for in-person-trained interpreters and very good (0.71) for e-trained interpreters. Median intrainterpreter agreement was 0.9 for both in-person-trained and e-trained interpreters. Visual and quantitative assessments were concordant in 88.9% of scans for in-person-trained interpreters and in 87.7% of scans for e-trained interpreters. CONCLUSION Visual assessment of florbetaben images was robust in challenging scans from elderly end-of-life individuals. Sensitivity, specificity, and interinterpreter agreement were high, independent of expertise and training method. Visual assessment was accurate and reliable for detection of plaques using BSS and immunohistochemistry and well correlated with quantitative assessments.
Collapse
Affiliation(s)
- John Seibyl
- Molecular Neuroimaging LLC, New Haven, Connecticut
| | | | | | - Kenji Ishii
- Department of Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
| | | | - James B Leverenz
- Virginia-Puget Sound Health Care System and University of Washington, Seattle, Washington
| | | | | | - Masaki Takao
- Mihara Memorial Hospital, Isesaki, Japan Department of Neurology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan
| | - Hiroyasu Akatsu
- Fukushimura Hospital, Toyohashi, Japan Departments of Community-Based Medicine and Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Aichi, Japan
| | - Shigeo Murayama
- Department of Neurology and Neuropathology (the Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan Institute of Gerontology, Tokyo, Japan
| | | | | | | | | | | | - Marwan N Sabbagh
- Alzheimer's and Memory Disorders Division, Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona
| | | | | |
Collapse
|
45
|
Salas A, Blazquez R, Bullich S, Izquierdo S, López ML, Marzana I, Vilaplana C, Ramón F. [Benchmarking and Quality Management Indicators Programme. Spanish experience]. Rev Calid Asist 2015; 30:337-341. [PMID: 26304145 DOI: 10.1016/j.cali.2015.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 06/30/2015] [Indexed: 06/04/2023]
Affiliation(s)
- A Salas
- Comisión de Acreditación de Laboratorios.
| | - R Blazquez
- Comisión de Acreditación de Laboratorios; Unidad de Calidad de Bioquímica, Departamento de Laboratorio Médico, Hospital Universitario de Móstoles, Móstoles, Madrid, España
| | - S Bullich
- Comisión de Aseguramiento Externo de la Calidad, Aseguramiento de la Calidad y Comité de Acreditación de Laboratorios, Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC), Barcelona, España
| | - S Izquierdo
- Comisión de Acreditación de Laboratorios; Servicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, España
| | - M L López
- Comisión de Acreditación de Laboratorios; Laboratorio Catlab, Departamento de Calidad, Terrassa, Barcelona, España
| | - I Marzana
- Comisión de Acreditación de Laboratorios; Laboratorio de Análisis Clínicos, Hospital San Eloy, Barakaldo, Vizcaya, España
| | - C Vilaplana
- Comisión de Acreditación de Laboratorios; Laboratori de Referència de Catalunya, El Prat, Barcelona, España
| | - F Ramón
- Comisión de Acreditación de Laboratorios
| |
Collapse
|
46
|
Farré M, Pérez-Mañá C, Papaseit E, Menoyo E, Pérez M, Martin S, Bullich S, Rojas S, Herance JR, Trampal C, Labeaga L, Valiente R. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2015; 78:970-80. [PMID: 24833043 PMCID: PMC4243871 DOI: 10.1111/bcp.12421] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Accepted: 05/08/2014] [Indexed: 12/16/2022] Open
Abstract
AIM A close correlation exists between positron emission tomography (PET)-determined histamine H1 -receptor occupancy (H1 RO) and the incidence of sedation. Antihistamines with H1 RO <20% are classified as non-sedating. The objective was to compare the H1 RO of bilastine, a second generation antihistamine, with that of hydroxyzine. METHODS This randomized, double-blind, crossover study used PET imaging with [(11) C]-doxepin to evaluate H1 RO in 12 healthy males (mean age 26.2 years), after single oral administration of bilastine (20 mg), hydroxyzine (25 mg) or placebo. Binding potentials and H1 ROs were calculated in five cerebral cortex regions of interest: frontal, occipital, parietal, temporal, insula. Plasma bilastine concentrations, subjective sedation (visual analogue scale), objective psychomotor performance (digital symbol substitution test), physiological variables and safety (adverse events, AEs), were also evaluated. RESULTS The mean binding potential of all five regions of interest (total binding potential) was significantly greater with bilastine than hydroxyzine (mean value 0.26 vs. 0.13, P < 0.01; mean difference and 95% CI -0.130 [-0.155, 0.105]). There was no significant difference between bilastine and placebo. Overall H1 RO by bilastine was significantly lower than that by hydroxyzine (mean value -3.92% vs. 53.95%, P < 0.01; mean difference and 95% CI 57.870% [42.664%, 73.075%]). There was no significant linear relationship between individual bilastine plasma concentrations and total binding potential values. No significant between-treatment differences were observed for sedation and psychomotor performance. Twenty-six non-serious AEs were reported. Sleepiness or sedation was not reported with bilastine but appeared in some subjects with hydroxyzine. CONCLUSIONS A single oral dose of bilastine 20 mg had minimal H1 RO, was not associated with subjective sedation or objective impairment of psychomotor performance and was devoid of treatment-related sedative AEs, thus satisfying relevant subjective, objective and PET criteria as a non-sedating antihistamine.
Collapse
Affiliation(s)
- Magí Farré
- Human Pharmacology and Neuroscience Research Unit, Hospital del Mar Medical Research Institute-IMIM, and Universidad Autónoma de Barcelona-UAB, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Leverenz JB, Sabri O, Catafau AM, Barthel H, Seibyl J, Ghetti B, Ironside JW, Bullich S, Schulz-Schaeffer WJ, Hoffman A. IC‐P‐002: Impact of morphologically distinct amyloid ß (Aß) deposits on 18F‐florbetaben (FBB) PET scans. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
48
|
Catafau AM, Bullich S, Seibyl J, Barthel H, Ghetti B, Leverenz JB, Ironside JW, Schulz-Schaeffer WJ, Hoffman A, Sabri O. IC‐P‐001: Do cerebellar plaques influence
18
F‐florbetaben amyloid PET scan quantification? Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Catafau AM, Bullich S, Seibyl J, Barthel H, Ghetti B, Leverenz JB, Ironside JW, Schulz-Schaeffer WJ, Hoffman A, Sabri O. O4‐08‐03: Do cerebellar plaques influence
18
F‐florbetaben amyloid PET scan quantification? Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.07.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
50
|
Klein G, Sampat M, Staewen D, Suhy J, Bullich S, Santi S. P4‐178: A study of optimal SUVR cutpoints and reference regions for florbetaben PET. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|